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I 
 
Abstract 
 
 Image processing and analysis techniques find widespread use in clinical 
environments: information provided by medical imaging has a fundamental impact 
on patient health and quality of life. The aim of image processing and analysis 
methodologies is the diagnosis accuracy improvements and the assessment of 
treatment response by means of quantitative bio-markers in an efficient way. In 
addition, an early and efficacy prediction of therapy response in patients is a critical 
issue in the field of personalized medicine.  
 In the last few years, several criteria to assess therapy response in oncological 
patients have been proposed, ranging from anatomic to functional assessments. 
Changes in tumour size are not necessarily correlated with changes in tumour 
viability and outcome. In addition, morphological changes resulting from therapy 
occur slower than functional changes.  
 Nuclear medicine images show interesting characteristic information about the 
physiological properties of the oncological lesions. In addition, PET (Positron 
Emission Tomography) imaging allows for early prediction of therapy response after 
only a few days of treatment. Due to the nature of PET images (low spatial 
resolution, high noise and weak boundary), metabolic image processing is a critical 
task to enhance the current methodology performed by healthcare operators in 
clinical routine. 
 In this ph.D. Thesis, many issues in a real clinical environment have been 
addressed and a certain amount of improvements have been produced in the 
following areas: 
 Automatic and real-time delineation of biological tumour volumes  
 Automatic evaluation of therapy response in oncological patients  
 Multi-modal image delineation of brain metastases in patients who underwent 
Gamma-Knife treatment. 
 The proposed contributions have produced scientific publications in indexed 
computer science and medical journals and conferences. In addition, some home-
made tools have been developed to be used as components of Medical Decision 
Support Systems to enhance the current methodology performed by healthcare 
operators in clinical routine. 
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 These studies are part of an on-going research collaboration in the area of 
computer engineering between my Department and colleagues at the: 
 Dipartimento di Biopatologia e Biotecnologie Mediche e Forensi 
(DIBIMED), University of Palermo 
 Cannizzaro Hospital of Catania 
 Ospedale San Raffaele of Milano 
 Ospedale Giglio of Cefalù 
 Istituto di Bioimmagini e Fisiologia Molecolare (IBFM) Centro Nazionale 
delle Ricerche (CNR) of Cefalù 
working closely to nuclear medicine and radiologist physicians, radiation therapists, 
and technical operators, and following the common denominator of automatic and 
operator independent methods applied to medical imaging issues. 
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BTV: Biological Tumour Volume 
CT: Computerized Tomography 
DICOM: Digital Imaging and Communications in Medicine 
FBP: Filtered Back-Projection 
FDG: 8F-fluoro-2-deoxy-D-glucose 
GTV: Gross Tumour Volume 
HNC: Head and Neck Cancer 
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MRI: Magnetic Resonance Imaging 
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1 
Chapter 1 
 
 
Introduction 
 The medical imaging is a crucial field for diagnostic and treatment purposes. 
Several medical imaging techniques are available and their improvement is one of 
the most important goals in the health’s research. 
 
 
1. Medical Imaging 
 
 Medical imaging is characterized by great multitude of heterogeneous data 
enclosing several experts and expertise in different fields, such as physicians, 
engineers, biologists, and physics for disease staging and treatment purposes.  
 According to the source and the physical properties, the medical imaging 
techniques can be differentiated in two groups:  
 anatomical/structural images, and 
 functional images.  
 In particular, Positron Emission Tomography (PET), Computerized Tomography 
(CT), and Magnetic Resonance Imaging (MRI) are in-vivo tomographic techniques 
which allows to show axial, sagittal and coronal images without moving the patient. 
Furthermore, these techniques can be classified on the use of ionized or non-ionized 
radiation as well as external or internal sources. 
 To support clinical decisions is mandatory to develop computer-assisted methods 
of quantitative biomarker extraction by medical images. To date, the computational 
power is mature: an effort is mandatory to address this power to analyze and process 
medical data in the best possible way. Fast and operator independent approaches are 
the crucial keywords in clinical environment to obtain an effective impact in the 
work of medical operators involved in diagnosis and treatment assessment. 
 Developing computer decision support systems that integrate the knowledge of 
the medical experts, and facilitate the diagnostic procedure are need for a better 
patient management. In particular, computer-assisted methods for segmenting 
regions of interests (ROIs) in medical images are increasingly important in assisting 
and automating specific radiotherapy tasks.  
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 1.1.1 DICOM Protocol 
 
 The medical images produced by special diagnostic equipment, such as PET, CT, 
and MRI, are compliant with the DICOM (Digital Imaging and Communications in 
Medicine) standard.  
 DICOM standard was created by National Electrical Manufacturers Association 
(NEMA) and it enables users to retrieve images and related information from 
different medical imaging modalities with a standardized way allowing the 
communication between electronic devices and biomedical computing from different 
vendors facilitating the management of digital images. In this way, the introduction 
of new services that support the medical applications is facilitated: DICOM enables 
the integration of scanners, servers, workstations, printers, and network hardware 
from multiple manufacturers. 
 A DICOM file consists of a header (so called metadata) and image data. The 
header includes image related information such as image type, study, information on 
the mode of acquisition, resolution (height and width), colour, size of the voxel, 
number of stored bits, and patient’s information.  
 In conclusion, the DICOM standard describes a directory structure that facilitates 
access to medical images and related information. 
 
 
 1.1.2 PET Imaging 
 
 PET is a non-invasive nuclear medical imaging technique based on the 
visualization of functional processes showing complementary information with 
respect to anatomical imaging. It provides an in vivo measure of the tumor biological 
processes (Spieth & Kasner 2002). Among several PET radiotracers derived from 
isotopes, 18F-fluoro-2-deoxy-D-glucose (FDG) is a glucose analogue widely used in 
the evaluation of several neoplastic pathologies as well as in radiotherapy planning. 
FDG uptake is increased in tissue with a high metabolic rate, such as tumor or 
inflammation regions. These areas appear as hot spots on PET images. FDG PET is 
able to identify the location of many primary tumors and metastases offering the 
opportunity to radically change patient treatment (i.e. from radiotherapy to 
chemotherapy)  or the radiotherapy planning treatment volume (PTV) (Guido et al. 
2009). For these reasons, the oncology field is the most used and developed for PET 
study: this technique has been recognized as an adequate staging and restaging tool 
in various cancer types. In addition, metabolic changes are often faster and more 
indicative of the effects of the therapy with respect to morphological changes (Wahl 
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et al. 2009).  
 To obtain a tomographic study, many acquisitions of the same object at different 
angles are executed; the object is reconstructed in three dimensions using complex 
mathematical algorithms such as the Filtered Back-Projection algorithm (FBP) or 
iterative methods. After applying reconstruction algorithms, a digital image that 
represents the uptake distribution in the tissues is obtained.  
 
 
 
 
Figure 1  An example of PET study (coronal, sagittal, and axial imaging planes). 
 
 
 1.1.3 CT Imaging 
 
 CT is a diagnostic imaging technique which uses ionizing radiation. CT studies 
are acquired by rotating an X-ray source around the patient. X-ray sensors are 
positioned on the opposite side, and the patient's bed is continuously moved to obtain 
a helical acquisition mode. X-ray beam intensity exponentially decreases in extent to 
the mass attenuation coefficient: the beam will be more attenuated by tissues with a 
high atomic number. Vice versa, if the beam crosses a low density tissue, the 
attenuation will be less. In this way, high-density tissues appear clear (maximum 
attenuation) and lower-density tissue appear dark (minimum attenuation). 
 After reconstruction, the CT images reflect the attenuation of each voxel 
according to the Hounsfield scale, where air has a radio-density of -1000 Hounsfield 
Units (HU) and distilled water a radio-density of 0 HU. CT provides high resolution 
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morphological images of the body, with an excellent contrast between air, adipose 
tissue, soft tissue and bone. However, the soft tissue contrast is poor if compared to 
other imaging modalities such as MRI. Contrast agents may additionally be used to 
highlight some regions, such as the gastrointestinal tract or the blood vessels.  
 
 
 
 
Figure 2 An example of CT acquisition (coronal, sagittal, and axial imaging planes). 
 
 
 1.1.4 MR Imaging 
 
 MRI is based on the different relaxation times of tissues after being subjected to 
an electromagnetic stimulus:  
 T1-weighted images: the time T1, or longitudinal relaxation time is a measure 
of the time for which the protons to return to the initial equilibrium 
conditions, through the transfer of energy to the surrounding 
microenvironment (lattice), in order to obtain a T1-weighted SE sequence, 
using a short relaxation time (TR) associated with a short echo time (TE). On 
T1-weighted images, the cerebrospinal fluid is dark while the fat is brilliant.  
 T2-weighted images: the time T2, or transverse relaxation time, is a measure 
of the time taken by the spin of protons to get out of sync. This progressive 
desynchronization will void the transverse magnetization. A sequence to get a 
T2-weighted sequence will have a long TR associated with a long TE. 
Liquids or at least very hydrated tissues, appear bright white in T2-weighted 
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images. 
 The relaxation time of a tissue is related with its water content. 
 MRI provide excellent soft tissue contrast. For this reason, MRI is widely applied 
in the diagnosis and treatment of neurological, cardiovascular, musculoskeletal, liver 
and gastrointestinal diseases. Moreover, contrast can be further enhanced through the 
injection of a contrast enhancement agent. 
 
 
1.2 Multimodal Medical Imaging 
 
 PET/CT or PET/MR imaging merges anatomical and functional information. This 
combination is clinically advantageous but it suffers from a number of practical 
problems. It is both expensive and time consuming for patients to undergo separate 
imaging studies. In addition, patient images must be aligned, or registered, before 
successful integration due to the patient position change between different imaging 
sessions. To overcome these issues, the development of hybrid systems has been 
carried out. In this way, multimodality medical imaging requires a single imaging 
session. This provides anatomical images that are inherently registered with the 
functional data.  
 To date, the availability of multimodality PET/CT (or PET/MRI) systems, 
providing functional PET images integrated with morphological CT (or MRI) 
images, allow physicians to accurately localize and characterize oncological lesions 
for a correct interpretation in most cases. PET images have a low spatial resolution 
and anatomical imaging techniques are still needed to localize and characterize 
abnormal regions. The diagnostic accuracy of the combined systems has proven 
superior to single techniques thanks to their complementary features (Schwartz et al. 
2005). The high contrast of PET images and high spatial resolution of CT or MRI 
images are then fused in multimodal images (see figure 3). 
 In the case of non-hybrid systems, the multimodality registration problem has 
been partly solved by recent developments in image processing. The majority of 
methods are automatic and do not require external markers. The clinical 
interpretation of registered anatomical and functional information is then performed 
by displaying the images either simply side-by-side or as a single fused image. 
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Figure 3 An example of PET/CT study (coronal, sagittal, and axial imaging planes). 
 
 
1.3 Radiation Therapy Planning 
 
 Radiotherapy aims to deliver the necessary therapeutic dose of ionizing radiation 
to the oncological lesions minimizing irradiation to normal tissues. In this way, 
radiation is delivered to target to damage and to kill the cancerous cells stopping 
them from regenerating. Since both cancer and healthy tissues are affected by 
radiation, any treatment plan should be designed in such a way that the radiation 
dose delivered to the tumor is high enough to destroy the cancer cells avoiding the 
delivery of excessive doses of radiation to surrounding normal tissue. Precise tumour 
volume delineation is a very critical step in order to ensure safe and effective 
radiation therapies. 
 The Radiation Therapy Planning (RTP) is to implement the treatment strategy 
assigning the desired dose to the various ROI. Recent advances in radiotherapy, such 
as intensity modulated radiation therapy, have improved the dose painting of RTP. 
These techniques enable a precise delivery of a high dose to the target maintaining a 
low radiation dose to nearby critical organs. However, the hardware precision in the 
delivering radiation dose is far greater than the software precision in the target 
volume delineation: accurate target volume definition is essential for escalating the 
radiation dose without increasing normal tissue injury.  
 CT and MRI are considered to be the standard for target volume delineation in 
many cancer district. Radiotherapy results based on morphological target volume 
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delineation are disappointing due to the radio resistance of the tumor and/or 
inadequate dose to target due to missed lesion. CT or MRI imaging may not show the 
viable extension of tumors and not localize isolated positive lymph nodes (Lauve et 
al. 2004). To improve these results, PET has been introduced in the radiotherapy 
field to assist the radiation oncologist in RTP: within the Gross Tumor Volume 
(GTV), defined on anatomical images, it is possible to define target volumes based 
on functional area (BTV – Biological Target Volume) and to apply a strategy that 
will deliver radiation to these regions. Though the use of PET images has been 
shown to improve target volume definition by reducing intra and inter-observer 
variability compared to CT images only (Ciernik et al. 2003).  
 
 
1.4 Thesis Outline 
 
 The thesis is structured as follows: 
 Chapter 2 describes the state-of-the-art of segmentation approaches in 
medical imaging. 
 Chapter 3 describe an innovative graph based approach for BTV delineation. 
 Chapter 4 presents clinical applications to assess the treatment response in 
oncological patients. 
 Chapter 5 describes a delineation approach for Gamma Knife treatment 
purpose: the multimodal segmentation is described. 
 Chapter 6 shows the experimental results. 
 Discussion and conclusion about this thesis, and some possible direction for 
future research. 
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Chapter 2 
 
 
Review of the State of the Art 
 
 
 
2.1 Medical Image Segmentation 
 
 Image segmentation is a fundamental and critical task in numerous biomedical 
imaging applications. It corresponds to extract a target out of an image identifying 
edges and areas of similar features.  
 Various delineation methods have been proposed in the literature. Each 
segmentation method has a different approach to find the optimal segmentation: 
depending on the application, appropriate segmentation algorithm must be chosen. It 
is impossible to make a categorical statement; different segmentation methods have 
different goals, and each method may be useful in different imaging applications.  
 In this study, the aim is to segment functional and anatomical regions for RTP. In 
the next paragraphs, various methods for BTV and multimodality image delineation 
are discussed. 
 
 2.1.1 PET Segmentation 
 Most of the segmentation techniques on medical images have been applied on CT, 
MR or ultrasound images and not on PET images since PET has received increasing 
attention only in recent years in order to incorporate metabolic information in RTP 
and to evaluate early treatment response in oncological patients.   
 To date, clinical analyses of PET studies are performed on software platforms 
with predefined window-level setting. This setting can be liberally modified by the 
nuclear physician, altering the visual appearance of PET lesions. The manual 
segmentation approach is then dependent on the experience of the nuclear physician 
limiting the measurement accuracy. In addition, the manual segmentation is time-
consuming and impaired by inter and intra-observer variability. 
 Currently available tumor delineation methods in PET imaging are based on a 
fixed threshold of the maximum tracer uptake value in the lesion. Other methods 
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based on fuzzy c-means (FCM) (Zaidi et al. 2002), region growing (Li et al. 2008) or 
watershed segmentation (Geets et al. 2007) have been suggested, but few validation 
studies are available and there is no consensus for a proper BTV delineation method 
with no clear guidelines on how to incorporate metabolic data into target delineation 
(Schinagl et al. 2007). Moreover, PET delineation approaches can be categorized on 
the basis of anatomical sites or radio-tracers used and, according to a comprehensive 
review of segmentation algorithms in PET imaging (Zaidi & El Naqa 2010), some 
segmentation methodology categories can be identified. 
 Image threshold methods are the most widely used due to their intuitive basis and 
simple implementation. Usually, each PET image voxel is initially converted into its 
corresponding body-weight Standardized Uptake Value (SUV). The SUV is a widely 
used PET semi-quantitative parameter, calculated as a ratio of tissue radioactivity 
concentration and FDG injected dose at the time of injection divided by body weight. 
Subsequently, a fixed, or adaptive, or iterative threshold (Ford et al. 2006; Drever et 
al. 2006; Drever et al. 2007; Kao et al. 2010) based on phantom simulations and on 
scanner hardware features is calculated. An absolute 2.5 SUV value, independent of 
background and lesion volume, was proposed by Paulino et al. (Paulino et al. 2005) 
to discriminate benign from malignant lesions and to delineate the BTV. This 
approach is very controversial and not accepted by the whole scientific community. 
However, some fixed threshold methods based on analytical equations extracted 
from realistic phantom experiments can have a better accuracy with respect to more 
complex adaptive or iterative approaches. These techniques need to be calibrated for 
each PET scanner and should not be used without optimization. Generally, image 
threshold methods are inter- and intra-operator independent but strongly scanner 
dependent, requiring a significant effort in the calibration data to identify the 
equation parameters. In addition, they are too sensitive to image noise and 
heterogeneity and partial volume effect (PVE) due to the limited spatial resolution of 
the PET scanner (Zaidi & El Naqa 2010). 
 Region growing is a recursive algorithm that groups pixels or sub-regions into 
larger regions. The grouping is based on predefined criteria, such as grey level 
threshold values. A region growing usually starts off with one seed point and then 
recursively add neighbouring pixels that fulfil the criteria to the region. Different 
connectivities can be used, in 2-D region growing the choice is usually between four 
and eight-connectivity. The algorithm ends by itself when no more pixels fulfil the 
criteria on a pixel level (Li et al. 2008). 
 Supervised and unsupervised learning methods such as artificial neural networks 
(ANN), support vector machines (SVM), k-means algorithms, FCM algorithms are 
efficient but only in large lesions of simple shape. These approaches discriminate 
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target from background based on a set of image features. However, supervised 
algorithms (ANN and SVM) have limited application in PET imaging, unlike in the 
MRI or CT fields, due to high heterogeneity that makes the recognition of stable 
features in the training set difficult. On the other hand, clustering methods such as 
FCM or Fuzzy Locally Adaptive Bayesian are optimal for the fuzzy nature of the 
PET lesion edge where a finite number of levels, rather than only two (foreground 
and background), is used to label voxels within the target area (Zaidi et al. 2002; Hatt 
et al. 2009). The main issue is the correct identification of the cluster number; Zaidi 
et al. (Zaidi et al. 2002) started the algorithm with an oversized number of clusters 
followed by a merging process to group clusters with similar properties to reach a 
number of clusters in agreement with uniform attenuation areas based on anatomical 
delineation. However, learning methods require high computational steps, especially 
in supervised methods, and they are sensitive to image heterogeneity and to study 
protocol variability, as for example scanner characteristics, PET radiotracers, 
radiotracer injected dose and interval between radiotracer injection and examination 
start.  
 Variational approaches are based on gradient differences between target and 
background regions attempting to exploit information provided by intensity variation 
(Wanet et al. 2011). They require smooth regions with reliable boundary information 
but PET images are characterized by low contrast. In the study proposed by El Naqa 
et al. (El Naqa et al. 2007), deformable active contour models are computed as 
directional gradients by means of energy minimization. These approaches are 
mathematically efficient but require an initialization and are sensitive to image noise 
and subject to numerical fluctuation.  
 
 2.1.2 Multimodal Segmentation 
 In clinical routine, it is highly desirable to have both functional and structural 
quantifiable information so the disease can be both identified and localized, 
potentially resulting in an earlier diagnosis and more effective treatment plan.  A 
concise but complete review of the state of the art regarding multimodal co-
segmentation approaches is reported in the following. 
 Several studies approach PET/CT tumor identification and characterization in 
radiation therapy scenarios. In (Yu et al. 2009), co-registered FDG-PET/CT were 
used for the textural characterization of head and neck cancer (HNC) for 
radiotherapy treatment planning. After a manual segmentation on co-registered 
PET/CT images (performed by an experienced radiation oncologist), useful textural 
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features were selected for distinguishing tumor from normal tissue in HNC subjects. 
Both k-nearest neighbours (KNNs) and decision tree (DT)-based KNN classifiers 
were employed to discriminate images of cancerous and healthy tissues. Han et al. 
(Han et al. 2011) presented a Markov random field (MRF)-based co-segmentation of 
the PET/CT image pair with a regularized term that penalizes the segmentation 
difference between PET and CT. This graph-based method utilizes the strength of 
PET and CT modalities for target delineation in a group of 16 patients with HNC. 
Background and foreground seed voxels must be always manually identified by the 
user. A similar approach is reported in (Song et al. 2013), where the segmentation is 
seen as a minimization problem of a MRF model, which encodes the information 
from both modalities. This optimization is solved using a graph-cut based method, by 
constructing two sub-graphs for PET and CT segmentation, respectively. The 
algorithm was validated in robust delineation of lung tumors on 23 PET/CT datasets 
and two HNC subjects. A further MRF-based systematic solution for the automated 
co-segmentation of brain PET/CT images into grey matter, white matter and CSF 
regions is exposed in (Xia et al. 2012). A PET/CT image pair and its segmentation 
result are modelled as a MRF triplet, and segmentation is eventually achieved by 
solving a maximum a posteriori (MAP) problem using the expectation maximization 
(EM) algorithm with simulated annealing. The overall MRF-MAP model was tested 
both on both simulated and real patient PET/CT data. 
 The authors of (Potesil et al. 2007) proposed a method for automated delineation 
of tumor boundaries in whole-body PET/CT by jointly using information from both 
PET and diagnostic CT images. After an initial robust hot-spot detection and 
segmentation performed in PET, a model for tumor appearance and shape in 
corresponding CT structures is learned by weighted non-parametric density estimate. 
This voxel-based CT classification is then probabilistically integrated with PET 
classification using the joint likelihood ratio test technique to derive the final 
segmentation. The algorithm was tested on patient studies with lung and liver tumors 
identifiable in both the PET and CT images acquired using the same scanner.  
 Yezzi et al. (Yezzi 2001) introduced a geometric variational framework that uses 
active contours to simultaneously segment and register features from multiple 
images. The key aspect of this approach is that multiple images may be segmented 
by evolving a single contour as well as the mappings of that contour into each image 
during feature-based realignment steps. The results of three experiments on MRI/CT 
images of the head and the spine are reported. Also the authors of (El Naqa et al. 
2007) developed variational methods based on multivalued level set deformable 
models for simultaneous 2D or 3D segmentation of multimodality images consisting 
of combinations of co-registered PET, CT, or MRI datasets. In particular, only three 
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patients are considering: a non-small cell lung cancer case with PET/CT, a cervix 
cancer case with PET/CT, and a prostate patient case with CT/MRI. In addition, CT, 
PET, and MRI phantom data were used for quantitative validation of the proposed 
multimodality segmentation approach. 
 An automatic algorithm for the co-segmentation of HNC based on PET/MRI data 
was proposed in (Leibfarth et al. 2015), in order to standardize tumor volume 
delineation. For both imaging modalities tumor probability maps were derived, 
assigning each voxel a probability of being cancerous according to its signal 
intensity. A combination of these maps was subsequently segmented using a 
threshold level set algorithm. The algorithm processes both the anatomical T2-
weighted MRI and FDG-PET data concerning 10 HNC patient datasets acquired in a 
combined PET/MRI system. 
 The group led by Bagci developed co-segmentation approach in multimodal 
medical imaging, using the Random Walker (RW) algorithm (Bagci et al. 2013) and 
unifying graph representation of each image modality in a single product lattice. The 
overall method results in a fully automatic framework, providing an automated 
object detection via interesting uptake region algorithm to avoid users foreground 
and background seed detection. Afterwards, prior to the initiation of the 
segmentation process, these identified seeds are propagated to the corresponding 
anatomical images. Although no significant anatomical and functional changes 
between the scans have to be assumed, the study used PET, PET/CT, MRI/PET, and 
fused MRI/PET/CT scans from 56 patients who had various lesions in different body 
regions.  
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Chapter 3 
 
 
Image Segmentation in PET 
 
 
 Due to the nature of PET images (low spatial resolution, high noise and weak 
boundary), the BTV varies substantially depending on the algorithm used to 
delineate functional signal in PET images. Visual delineation is widely-used, but it is 
strongly operator-dependent, even if easily applicable. It is potentially inaccurate 
because susceptible to the window level settings and subject to both intra and inter-
operator variability. In addition, the manual segmentation is time-consuming and 
impaired by inter and intra-observer variability. For this reason, the development and 
implementation of robust, fast, accurate, operator and scanner independent 
segmentation method is mandatory to properly use the crucial information provided 
by molecular imaging. 
 
 
3.1 Random Walks on Graphs Method 
 
 Graph based methods are used to find the globally optimal segmentation of 
images. They provide a foreground and background recognition in images in which 
the seeds are specified by user input.  
 An undirected graph G can be represented as a pair G = (V,E) with nodes v ∈ V 
and edges e ∈ E ⊆ VxV. A node vi is a neighbour of another node vj if they are 
connected by an edge eij with a weight wij (wij=wji being an undirected graph).  
 The graph-based segmentation method represents a DICOM image as a graph in 
which the voxels are its nodes and the edges are defined by a cost function that maps 
a change in image intensity to edge weights.  
 The graph cut algorithm (Boykov et al. 2001) tries to partition the target and 
background edges detecting bottlenecks in a weighted graph. This approach is a 
computationally difficult algorithm and it has no exact solution. In addition, since 
this method tries to minimize the sum of edge weights in the cut, it may return very 
small segmentations as a result of low contrast or noise. To solve this problem, 
known as “small-cut”, many seeds are needed.  
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 The Random Walks on Graphs (RW) algorithm was developed by Grady (L. 
Grady 2006) to resolve these issues in the computer vision domain and then was 
extended for image segmentation (Bagci et al. 2011). Aside from the fact that both 
graph cuts and RW are graph-based methods, they are actually quite different. Rather 
than treating the segmentation as a max-flow/min-cut problem, RW treats the 
segmentation as the solution to a linear system with an exact solution. In addition, 
RW, with respect to graph-cut, is less susceptible to “small cut” behaviours and is 
more efficient in terms of handling ambiguities among object boundaries.  
 RW is very accurate in noisy and low contrast images, such as PET images.  
 The PET image is then converted into a lattice where some voxels are known 
(nodes with labels specified by user input) and some voxels are not known. The 
delineation problem is to assign a label to unknown nodes. This is done by trying to 
find the minimum cost/energy among all possible scenarios in the graph to provide 
an optimal segmentation. The RW algorithm can be used to partition the nodes into 
two disjointed subsets representing lesion and background. The RW partition is 
derived from the probability that a “random walker” starting at a source node, first 
reaches a node with a pre-assigned label, visiting every node in the image. Then, the 
RW problem is to determine the highest probabilities for each pixel to reach the 
target node (target seed) and has the same solution as the combinatorial Dirichlet 
problem. The Dirichlet integral is defined as: 
 
D[u] = ½ ∫ |∇U|2 dΩ     (1) 
 
for a field U and region Ω. Its solution is given by a harmonic function that satisfies 
the Laplace equation: 
 
∇2U = 0        (2) 
 
 The combinatorial Laplacian matrix (Lij) is a sparse matrix defined as: 
• Σwij  if i = j 
• - wij  if i and j are adjacent nodes 
• 0 otherwise 
 
 It can be partitioned into four sub-matrices:  
 
      [
𝐿𝑀 𝐵
𝐵𝑇 𝐿𝑈
]                         (3)  
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where LU is a sub-matrix of edge weights for the un-labelled voxels and LM is a 
sub-matrix of edge weights for the labelled nodes. B is a sub-matrix of edge weights 
corresponding to the labelled voxels. 
The harmonic function can be found by solving a system of linear equations as 
follows: 
 
 LU X = −B
T
 M          (4) 
 
M is a matrix of 0 or 1 corresponding to the boundary conditions of seeds. X is 
the probability for each node being a member of the labels: a threshold of 50% is 
chosen to discriminate the foreground from the background creating a voxel binary 
mask, so that: 
• target node value = 1 if its probability ≥ 50% 
• background node value = 0  if its probability < 50%. 
 
 This threshold implies that any pixel with less than a 50% chance of being in the 
foreground is rejected. 
 The weights wij between nodes, necessary for the walk moving on the graph, are 
constructed using a Gaussian function based on image intensity values: 
 
 wij = exp(-β(gi-gj)^
2
)  (5) 
 
where both gi and gj are the image intensity values at voxels i and j; β is a free 
parameter depending on the user. RW measures the “betweenness” through the 
starting pixel (foreground seed) to the un-labelled pixel determining the highest 
probabilities for assigning labels to the nodes.  
 
3.2 Random Walks on Graphs in PET imaging 
 
 The RW algorithm has been modulated to adapt to the PET application domain in 
order to incorporate metabolic information in the radiotherapy field. The Gaussian 
weighting function for the PET image is defined as: 
 
     wij = exp(-β(SUVi-SUVj)^
2
)         (6) 
 
where  
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     SUV = R/ (I / W)                          (7) 
 
 R is the radioactivity activity concentration [kBq/ml], I is the decay-corrected 
amount of injected radiotracer [kBq], and W is the patient’s weight [g]. The SUV, 
the most common semi-quantitative parameter used to estimate radiotracer 
accumulation within a lesion in clinical practice, normalizes the voxel activity 
considering acquisition time, administered activity and patient’s weight. Hence the 
PET image is converted into a lattice where the SUV of each voxel is mapped to wij. 
Then, each random walker is driven by the gradient field and the SUV of PET 
images: the probability of each node is inversely proportional to the contrast between 
the voxels which does not allow the walks to cross the edges. 
 
 
3.3 Clinical Applications 
 
 The accuracy of segmentation methods can be assessed using phantoms 
containing targets of simple shapes, such as spheres, simulating tumor lesions. 
Actual lesions are irregular, heterogeneous and can have complex shapes with 
respect to phantom spheres. For a realistic evaluation of delineation methods, it is 
important that irregular and inhomogeneous volumes are considered: the crucial step 
is to try delineation methods in actual patient situations. For this reason, two 
different solutions for BTV delineation in Head and Neck Cancer (HNC) and brain 
cancer have been implemented to overcome the RW issues:  
1. the RW algorithm requires a set of pre-labeled seeds, which are generated 
interactively. The delineation is sensitive to the location of the pre-labeled 
voxels.  
2. the RW algorithm is sensitive to the choice of β weighting factor in (5). 
 
 
 3.3.1 BTV delineation: Head and Neck Cancer  
 
 Radiotherapy is commonly used in the treatment of head and neck cancer. Figure 
4 shows a bifurcated PET/CT lesion in an oncological patient with HNC; the volume 
of a complex metabolic lesion may evolve splitting into more parts or merging in a 
single part or both of these. Thus, a complex shape requires an accurate and efficient 
method of segmentation able to follow the lesion in its whole volume.  
An enhanced version of the Random-Walk algorithm has been implemented:  
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1. The proposed algorithm incorporates k-means clustering to select the target 
seeds along the whole tumor volume performing a precise delineation of 
complex lesions 
2. An adaptive probability threshold is proposed to discriminate between target 
and background regions rather the fixed one of the original RW method. The 
adaptive probability threshold takes into account the intensity changes 
between adjacent PET slices along the metabolic volume and it makes the 
algorithm not subjective. 
 
 
Figure 4 A PET lesion that evolves splitting into two parts and merging in a single part along its 
volume. 
 
 
 3.3.1.1 RW algorithm with K-means: K-RW 
 
 The RW delineation is sensitive to the location of the pre-labelled voxels. An 
automatic method of background and foreground seed detection is then proposed: the 
implemented method is based on k-means clustering to make the BTV delineation 
process feasible in complex and heterogeneous lesions, such as bifurcated lesions. 
 The user draws a line on the coronal PET image along the target, and the axial 
slice with maximum SUV (SUVmax) is automatically identified and showed to the 
user that draws a new line along the lesion. This approach allows to properly 
delineate the PET tumor, excluding false positives (normal structures such as brain, 
heart, bladder, and kidneys that normally have high FDG uptake).  
 The algorithm can be split in two main steps: the pre-segmentation step to 
automatically detect the RW seeds, and the segmentation step to delineate the final 
metabolic tumor. The initial target seeds are the voxels corresponding to the line 
drawn by the user (target seed line).  
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The delineation method is achieved by following these steps: 
1. The target seeds with a SUV less than 30% of the SUVmax are removed to 
avoid eventual necrotic or background area.  
2. The neighbourhood through searching in 8 directions with respect to the voxel 
with SUVmax is explored to detect background seeds. For all 8 directions, the 
location of the first voxel with a value less than 30% of the average of target 
seed SUVs is identified. Those 8 voxels are marked as background seeds. 
3. The RW delineation performs a “roughly” pre-segmentation by utilizing the 
target seed line and the 8 background seeds. The probability threshold to 
discriminate target from background voxels is fixed at 50%: any voxel with 
less than a 50% chance of being in the foreground is rejected. 
4. The k-means algorithm is used to automatically select k-cluster centres within 
the pre-segmented lesion. In a complex volume, a lesion can be divided into 
two or more areas with different hot peeks. This algorithm follows the 
evolution of the target in the whole volume identifying centroids of hot 
regions. In the case of a homogenous target (such as a sphere in phantom 
studies), the algorithm returns a single centroid. The k value is automatically 
inferred. 
5. The centroids (one or more) and the voxels within the pre-segmented lesion 
with a SUV greater than 90% of SUVmax are identified as new target seeds. 
6. The RW algorithm performs the segmentation by utilizing the seeds identified 
in step 2 and 5. 
7. For the first slice (the slice with SUVmax), the user can manually change the 
probability threshold, rather the fixed one of 50%, to discriminate target from 
background voxels in order to select the value that optimizes the segmentation 
task: the probability threshold chosen by the user in this slice remains fixed 
for the whole volume. 
 This process is repeated slice by slice to obtain the whole lesion volume and it is 
performed in parallel for slices above and below the first one. In particular, the seeds 
are propagated in the next slices until no segmentation or abnormal increment of 
target seeds is verified. 
An overview of the K-RW (K-means RW) seed localization method is outlined in 
figure 5.  
 About step 4, the k-means algorithm takes as input the matrix that contains the 
pre-segmented lesion. It returns the coordinates of the k centroids of hot regions.  
The k value is automatically inferred: 
• k=2 if the target seed line contains voxels with SUV greater than 30% of the 
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SUVmax. This check allows excluding necrotic or background area. Lesion and 
background regions will represent the two clusters. 
• k=n+1 if the start target seed line contains seeds with SUV less than 30% of 
the SUVmax. These voxels are considered as belonging to the background or 
necrotic region: the seed line passes from a “hot” region to another “hot” 
region. k= n+1 indicates the n “hot” regions corresponding to the segment 
number of the target seed line after the thresholding step, and the background 
region (various background regions correspond to a single region). 
 
 
Figure 5 Pre-segmentation and segmentation steps in the slicemax are shown in (a–c). The user draws a 
line on the lesion (a). Then, the RW algorithm performs a rough pre-segmentation step (region of 
interest in (b)) to detect the target and background seeds used to perform the final segmentation step 
(c). 
 
 
 3.3.1.2 RW algorithm with adaptive probability threshold: AK-KW 
 
 The RW method depends on the choice of the β factor in the Gaussian weighting 
function in equation 5. In the paper reported in (Bagci et al. 2013), the authors 
improved RW robustness in PET imaging but they did not deal with the dependence 
of this parameter. In (Onoma et al. 2014), the authors take into account this limitation 
suggesting the use of the Euclidean distance between adjacent nodes. Nevertheless, 
the authors do not take in consideration the issue of complex lesions that may evolve 
splitting into more parts or merging in a single part or both of these, such as HNC in 
which the Euclidean distance is not an optimal solution. To overcome these 
limitations, we propose an approach based on the RW probability matrix to obtain an 
adaptive probability threshold rather than a fixed one of 50%. In this way, the 
proposed method becomes independent of the choice of β factor because β influences 
how quickly the probability decreases with increasing intensity: a high β value 
reduces the weight of walker, which weakens the connection between the adjacent 
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nodes and underestimates the target volume. Vice versa, a low β value increases the 
weight, which overestimates the target volume. The adaptive probability threshold 
takes into account the intensity changes between adjacent PET slices along the whole 
metabolic volume because the probability threshold changes slice after slice to 
discriminate target from background voxels.  
 The algorithm is the same as the previous one descripted in paragraph 3.3.1.1 
except for step 7 where the probability threshold is automatically inferred by the 
system, slice after slice (the probability threshold changes during volume 
delineation). The probabilistic output of segmentation is processed to obtain an 
adaptive threshold value (P) by following these steps: 
1. Calculate the mean (M) of the probability values inside a large pre-segmented 
lesion obtained using a fixed probability threshold of 80%. Identification of 
two groups of voxels: 
• Voxels with a probability < M. 
• Voxels with a probability ≥ M. 
2. Calculate the probability means (P1 and P2) of the two groups. 
3. The adaptive threshold value is then calculated as P=½ (P1+ P2). 
Any voxel with less than a P% chance of being in the target is rejected: 
 target voxel value = 1 if its probability ≥P% 
 background voxel value = 0 if its probability < P% 
 This method follows the whole lesion volume taking into account the gradient of 
intensity and contrast changes of the PET lesion in different slices. 
 
 
 3.3.2 BTV delineation: Brain Cancer 
 
 FDG PET is not able to detect metabolic active regions in cerebral area, because 
the whole brain has a high uptake of glucose appearing as a hyper-intense area. 
Consequently, another radio-tracer must be used in order to have functional 
information about brain lesions. 11C-labeled Methionine (MET) is an amino acid 
that shows a greater transport within the active cancer cells. It has been reported that 
the extent of tumour cell invasion can be detected more clearly by MET PET than by 
CT or MRI (Nariai et al. 2005). Using MET PET imaging, it is possible to define the 
BTV to apply a strategy that will deliver radiation to these regions. 
 A fully automatic and operator independent method for the BTV delineation of 
brain metastases based on an extension of the RW algorithm is then proposed. Target 
and background RW seeds are automatically identified and an adaptive threshold, 
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likewise to that used in HNC patient study, is proposed. Due to these improvements 
proposed, the method is called automatic and adaptive random walk (AA-RW). 
 
 
 3.3.2.1 Fully Automatic Method 
 
 The fully automatic identification of target and background seeds is feasible 
because the MET PET datasets for Gamma-Knife treatments include only the brain 
area avoiding the possible presence of false positives in other anatomic regions. 
Differently, in total body PET examinations, such as those carried out in our 
previous clinical study, a user interaction to manually identify the target lesion is 
always needed (normal structures such as brain, heart, bladder, and kidneys normally 
have high FDG uptake).  
 To obtain a fully automatic and operator independent method, the target and 
background seeds are localized by following these steps: 
 The PET slice with the highest SUV (SUVmax) is identified 
 The n nodes with a SUV greater than 95% of SUVmax are marked as target 
seeds 
 The neighbourhood of the node with SUVmax through searching in 8 directions 
is explored to identify the nodes with a SUV less than 30% of the average of 
target seed SUVs. In this way, 8 background nodes are identified. 
 
     3.3.2. Adaptive probability threshold: AA-RW 
 
 The probabilistic output of segmentation is processed to obtain an adaptive 
threshold value (P) by following these steps: 
1. Calculate the mean (M) of the probability values inside a large pre-segmented 
lesion obtained using a fixed probability threshold of 80%. Identification of 
two groups of voxels: 
• Voxels with a probability < M. 
• Voxels with a probability ≥ M. 
2. Calculate the probability means (P1 and P2) of the two groups. 
3. The adaptive threshold value is then calculated as P=½ (P1+ P2). 
Any voxel with less than a P% chance of being in the target is rejected: 
 target voxel value = 1 if its probability ≥P% 
 background voxel value = 0 if its probability < P% 
 This method follows the whole lesion volume taking into account the gradient of 
intensity and contrast changes of the PET lesion in different slices. 
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Chapter 4 
 
 
Metabolic Evaluation of Oncological Treatment s 
 
 FDG-PET imaging has been a fundamental impact in many fields of oncology and 
has been recognized as an adequate staging tool. The uptake quantification of 
oncological lesion is requested for a more accurate characterization of the tumour 
malignancy and a better patient monitoring after chemotherapy or radiotherapy 
treatments. Furthermore, the availability of in vivo quantitative biomarkers for 
cancer is crucial in perspective of personalized medicine and predictive medicine. 
Nevertheless, some drawbacks are evident when PET quantitative analysis are 
performed. PET quantiﬁcation is in fact strongly affected by the PVE (Soret et al. 
2007), as a consequence of the PET poor spatial resolution. For this reason, a PVE 
correction method has been implemented and evaluated in treatment monitoring 
(Gallivanone et al. 2011; Stefano et al. 2014) (see figure 6). 
 
 
Figure 6 PVE has a critical impact on PET SUV treatment monitoring. 
 
 In addition, metabolic changes assessed by PET imaging are often faster and more 
indicative of the effects of therapy with respect to morphological changes, providing 
a more rapid evaluation of the response to treatment (Wahl et al. 2009). Current 
generation PET/CT systems allow the integration of functional and morphological 
data leading to a better characterization and localization of the tumors and, 
consequently, a better diagnostic performance.  
 According to RECIST (Response Evaluation Criteria in Solid Tumors) 
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(Eisenhauer et al. 2009), therapy assessment on radiological imaging is based on a 
change in lesion size. When more than one measurable lesion is present at baseline 
all lesions up to a maximum of five lesions total representative of all involved organs 
should be identified as target lesions. A sum of the diameters for all target lesions is 
then calculated. 
 Evaluation of therapy response according to RECIST: 
 Complete Response (CR): Disappearance of all target lesions. 
 Partial Response (PR): At least a 30% decrease in the sum of diameters of 
target lesions, taking as reference the baseline sum diameters. 
 Progressive Disease (PD): At least a 20% increase in the sum of diameters of 
target lesions. In addition to the relative increase of 20%, the sum must also 
demonstrate an absolute increase of at least 5 mm. The appearance of one or 
more new lesions is also considered progression. 
 Stable Disease (SD): In another cases. 
 PET images are analysed semi-quantitatively by using the SUV.  The European 
Organization for Research and Treatment of Cancer (EORTC) has proposed 
metabolic criteria to evaluate the response after therapy by PET studies (Young et al. 
1999). In the same way, new standardized criteria to metabolically assess treatment 
response, PET Response Criteria In Solid Tumours (PERCIST), was proposed in 
2009 (Wahl et al. 2009). Key elements of PERCIST, with respect to EORTC, include 
performance of PET scans by a method consistent with the National Cancer Institute 
recommendations and with those of the Netherlands multicentre trial group, on well-
calibrated and well-maintained scanners 18.  
 
 
Figure 7 EORTC and PERCIST classifications. 
 
 According to the PERCIST protocol, the SULpeak is the SUV normalized to lean 
body mass calculated as the average within a 1 cm
3
 spherical VOI centred at the 
portion of the lesion with the highest 18F-FDG uptake in each patient. The SUL 
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threshold for a lesion to be reportable is (1.5xSULmean) + (2xSD of SULmean), being 
SULmean estimated on a reference VOI positioned on the right lobe of the liver. In 
cases of diseased liver, the VOI is positioned on the descending aorta and the 
threshold is (2xSULmean) + (2xSD of SULmean). Finally, in order to take into account 
non-pathologic variability PERCIST recommends comparing baseline and follow-up 
PET studies when the liver/aorta SUL variation is less than 20 percent. 
 Larson et al. (Larson et al. 1999), in 1999, introduced the Metabolic Tumour 
Volume (MTV) and the Total Lesion Glycolysis (TLG) to evaluate therapeutic 
response. TLG, defined as MTV x (average SUV within the MTV), combines the 
volumetric and SUV information, to try to obtain a better evaluation of the treatment 
response. These parameters can be considered prognostic markers, and are correlated 
with disease-free survival (DFS) and overall survival (OS). Nevertheless, the 
metabolic volume and, consequently, the TLG vary substantially depending on the 
method used to delineate functional positive tissues, due to the low spatial resolution 
and high noise level of PET images. For this reason, the developed graph-based 
algorithm, introduced in the third chapter, has been used.  
 The calculation of SUL over lesion and liver/aorta, accounting for all voxel data 
inside the VOI, the liver/aorta SUL comparison in different time points, and the 
lesion classifications, are a cumbersome procedure and needs the development of 
customized software. Ad-hoc stand-alone tool has been developed to implement 
RECIST, EORTC, PERCIST, MTV and TLG as a Medical Decision Support System 
to help clinicians in treatment response evaluation of oncological patients: the 
customized framework developed to carry out clinical studies is shown in figures 8, 
and 9. 
 
 
4.1 Lung Cancer 
 
 4.1.1 Evaluation of Erlotinib treatment response 
 
 In this clinical application, the value of PET for early prediction of tumour 
response to Erlotinib (Tarceva, Astellas Pharma Inc.) in patients with advanced or 
metastatic non-small cell lung cancer (NSCLC) after failure of at least one prior 
chemotherapy regimen is evaluated. In NSCLC the tyrosine kinase receptors are 
over-expressed or non-regulated: these receptors are therefore recognized as targets 
for cancer therapy.  Erlotinib is an epidermal growth factor receptor (EGFR)-tyrosine 
kinase inhibitor (TKI) that has been gradually used in the treatment for advanced 
NSCLC after the failure of more than one or two previous chemotherapeutic 
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regimens. Glucose metabolic activity reflects the response to EGFR TKI. 
 
 
 
Figure 8 The developed framework to automatically assess the treatment response. 
 
  
 
 
Figure 9 PERCIST classification of a treated patient. 
 
 Patients receiving Erlotinib neoadjuvant chemotherapy treatment (150 mg orally 
once daily for 45 days) undergo a FDG PET/CT scan before treatment (PETI) and 
after administration of 3 doses of Erlotinib at 48 h (PETII) for early monitoring.  A 
further metabolic follow-up is planned at the end of Erlotinib treatment, 45 days 
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from the start of therapy (PETIII). CT study, after the administration of 100 ml of 
intravenous iodate contrast material (Iomeprolo, Iomeron 300), is performed before 
and 45 days after the initialization of treatment. 
 For each PET study, the lesion presenting with the highest 18F-FDG uptake is 
considered (not necessarily the same lesion on three PET studies) according to 
EORTC, PERCIST and RECIST classifications to assess metabolic and anatomic 
response. In addition, the metabolic volume is calculated using the method described 
in the previous chapter (section 3.3.1).  
 
 
 4.1.2 Evaluation of Platinum-based therapy response 
 
 The purpose of this clinical application, is to evaluate the PET value for early 
prediction of tumour response to platinum-based therapy in patients with NSCLC. 
Patients receive a platinum-based chemotherapy according to the American Society 
for Clinical Oncology or European Society for Medical Oncology guidelines, with 
carboplatin or cisplatin in combination with another third generation agent. 
 Patients undergo a FDG PET/CT examination without contrast before platinum 
based chemotherapy and ~28 days after the initiation of therapy for early monitoring. 
Morphological diagnostic CT scans before and after the initiation of treatment are 
performed. The evaluation is carried out comparing the standard treatment response 
using RECIST with metabolic treatment response according to EORTC, PERCIST, 
TLG and MTV.  
   
 
4.2 Brain Cancer 
 
 Leksell Gamma Knife® (Elekta, Stockholm, Sweden) is a stereotactic radio-
surgical device to treat different brain disorders that are often inaccessible for 
conventional surgery, such as benign or malignant tumours. Stereotactic radiosurgery 
allows an accurate external irradiation (with a single, high dose and sharp dose 
gradient) to minimize doses given to adjacent critical brain structures. The gamma 
rays (generated by cobalt-60 [60Co] radioactive sources) are focused on the target 
through a metal helmet. It provides a safe and effective way of treating inaccessible 
cerebral tumours. 
 An examination to differentiate malign and benign tissue in brain tumours with 
great preciseness is the PET with the amino acid tracer 11c-methionin (MET).  
 Numerous studies have shown that the specificity of the MET PET for marking 
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tumour delineation and for the differentiation relapse versus radiation necrosis is 
higher compared with MRI.  
 The implemented segmentation method described in section 3.3.2 is used in 
patients with cervical metastases to evaluate therapeutic response in sequential scans. 
Patients undergo MET PET examinations before and 2 months after the Gamma 
Knife treatment.  Lesion segmentation is used to evaluate therapeutic response using 
SUVmax, MTV, and TLG variations in sequential scans.  
 
 
 
 
 
 
 
 
 
 
 
 
  
31 
Chapter 5 
 
 
Multimodal Image Segmentation  
 
 Anatomical GTV often does not match with BTV at all. Metabolic imaging could 
be used to provide additional information useful for treatment planning and enhanced 
tumour characterization. In this way, the BTV can be used to modify the GTV in 
order to treat the actual cancer region more precisely combining the complementary 
information of tissues from both anatomical and functional domains. For this reason, 
a robust joint anatomical/functional segmentation method, which simultaneously 
segments lesions in each image domain, is required. This task, named co-
segmentation, is a challenging problem due to: 
 unique demands and peculiarities brought by each imaging modality, and  
 lack of one-to-one region and boundary correspondences of lesions in 
different imaging modalities. 
 
 
5.1 Gamma Knife Treatment  
 
 Leksell Gamma Knife (Elekta) radiosurgery is a mini-invasive technique defined 
as the delivery of a single, high dose of radiation to obtain a complete destruction of 
brain lesions with an abrupt drop of dose to healthy tissue. It provides a safe and 
effective way of treating inaccessible brain tumours. The high preciseness of the 
irradiation is achieved by special stereotactic fixing, localization and positioning 
device (Leksell 1983). 
 Nowadays, the GTV for radiation treatment planning is identified on MRI. MRI is 
preferred over CT when soft-tissue contrast resolution must be highly detailed such 
as in brain malignancies. Even if MRI is characterized by a high spatial resolution, it 
contains just morphological information, without providing tumour biology 
information. GTV will not match with the functional area of the tumour, and 
metabolic imaging must be considered to assist the radiation oncologist in treatment 
planning (Levivier et al. 2002). 
 FDG-PET for BTV delineation shows limited clinical value in brain tumours. 
Only in a few patients, additional information are derived from FDG-PET for 
radiation treatment planning because of the low contrast between viable tumours and 
normal brain tissue, although FDG uptake is regionally related to anaplastic areas. In 
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fact, FDG is used as a tracer of glucose metabolism. The distribution of FDG is thus 
not limited to malignant tissue because FDG enters the cells according to glucose 
transport mechanism: it is known that FDG PET is not able to detect metabolic active 
regions in cerebral area, because the whole brain has a high uptake of glucose 
appearing as a hyper-intense area. Consequently, another radio-tracer must be used 
in order to have functional information about brain lesions.  
 [11C]-Methionine (MET) is a natural amino acid avidly taken up by brain cancer 
cells, whereas its uptake by normal brain is low. MET-PET discerns malign and 
benign tissue in brain tumours with great sensitivity and specificity, by localizing 
selectively in cancer regions of the brain. Numerous studies have shown that the 
specificity of the MET-PET for marking tumour delineation and for the 
differentiation relapse versus radiation necrosis is higher compared with MRI. In the 
paper reported in (Grosu et al. 2005), metabolic imaging was used for biological 
target delineation in 36 patients that showed a significantly longer median survival 
compared with the group of patients, in which target volume was merely defined by 
MRI. In addition, the extent of tumour cell invasion can be detected more clearly by 
MET-PET than by CT or MRI (Nariai et al. 2005).  
 Using MET PET imaging, within the GTV, it is possible to define the BTV to 
apply a strategy that will deliver radiation to these regions. Integration of PET in 
Gamma Knife treatment may contribute to a better management of brain metastases. 
 
 
5.2 Joint PET/MRI Segmentation Approach 
 
 The proposed multimodal method exploits PET and MRI computer-assisted 
segmentation methods, which have been properly combined together and improved. 
An image co-registration stage is mandatory in order to integrate and quantitatively 
compare MRI and PET modality imaging data. Figure 10 outlines the overall flow 
diagram of the proposed PET/MRI joint segmentation method. 
 
 
 5.2.1 BTV delineation 
  
 The fully automatic segmentation method described in section 3.3.2 is used to 
obtain the BTV. 
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Figure 10 Flow diagram of the proposed fully automatic PET/MRI joint segmentation method.  
 
 5.2.2 GTV delineation 
 
 The MRI tumour segmentation approach, based on unsupervised Fuzzy C-Means 
Clustering (FCM) and proposed in (Militello et al. 2015), is outlined. Nevertheless, 
the method is semi-automatic. User intervention is reduced to the selection of a ROI 
bounding area containing the cancer zone and no parameter setup is required. All the 
subsequently processing stages are accomplished on the MR images masked with 
this ROI bounding region. 
 Firstly, some pre-processing operations are applied: 
1. contrast stretching operation, by means of a linear intensity transformation, to 
convert the input intensity values into the full dynamic range; 
2. smoothing operation, using an average filter, to remove the MRI acquisition 
noise (i.e. due to static magnetic field non-uniformities). 
 The ROI segmentation based on unsupervised clustering is performed on MR 
images including brain tumours. FCM cluster analysis is an iterative machine 
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learning technique that classifies a dataset (i.e. a digital image) into groups (regions) 
(Bezdek et al. 1984). Mathematically, the goal of this algorithm is to divide a set of 
objects (statistical samples represented as vectors belonging to n-dimensional 
Euclidean space) into clusters (partitions of the input dataset), represented by 
centroids. A fuzzy partition is defined as a fuzzy set family such that each object can 
have a partial membership to multiple clusters. The matrix defines a fuzzy C-
partition of the set   through membership functions, whose values represent 
membership grades of each element to the i
th
 fuzzy set (cluster). 
 FCM is an optimization problem where the objective function must be iteratively 
minimized using a least-squares method. Two clusters are selected in order to 
suitably classify a hyper-intense lesion from the healthy part of the brain. In fact, in 
contrast-enhanced MR brain scans, metastases have a brighter core than periphery 
and distinct borders distinguishing them from the surrounding healthy brain tissue. 
As the brain tumours are imaged as hyper-intense enhancement regions, during the 
defuzzification step, the pixels that have the maximum membership with the 
brightest cluster are selected. 
 Since sometimes edema or necrosis (hypo-intense regions) could be present in 
some lesions and must be included in the planned target volume for radio-therapeutic 
purposes, the following post-processing refinements are required: 
1. small area removal, to delete any unwanted connected-components included by 
the highest intensity cluster. These small regions may be due to anatomical 
ambiguities when the lesion is located near high valued pixels, i.e. cranial bones, 
head skin or the corpus callosum; 
2. convex hull operation, to envelope the segmented lesion into the smallest 
convex polygon that contains the automatically segmented region, since brain 
metastases have a nearly spherical or pseudo-spherical appearance (Ambrosini et 
al. 2010). This operation comprises hole filling too, in order to include any 
necrotic core inside the segmented ROI; 
3. logical and morphological operations based on cluster analysis (FCM on the 
pre-processed image with   clusters), to include internal or adjacent necrotic areas 
do not detect by the previous convex hull operation. 
 
 
 5.2.3 BTV and GTV Co-registration 
 
 An image co-registration step is mandatory in order to bring the different MRI 
and MET-PET datasets, concerning the same patient, into the same space. In this 
way, it will be possible to make quantitative and meaningful comparisons between 
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the brain lesion segmentation results achieved by both MRI and PET segmentation 
methods. MRI is used as reference (target) image while the PET is the source 
(floating) image, because MRI conveys more anatomical information than PET. 
Indeed, PET imaging is characterized by weak boundaries and have a lower spatial 
resolution than MRI. Realignment and re-slicing operations are thus required to get 
an one-to-one mapping between PET and MRI slices. From the algorithmic 
perspective, image co-registration involves finding parameters (i.e. geometric 
transformation matrix) that either maximize or minimize some objective function. 
However an accurate interpolation method is clearly required, by which the floating 
and target images are sampled when being represented in different spaces (Pluim et 
al. 2003). 
 PET/MRI inter-modal 3D registration was performed using SPM 12 (Statistical 
Parametric Mapping, Wellcome Trust Centre for Neuroimaging, University College, 
London, UK), a software package designed for the analysis of brain imaging data 
sequences (Friston 2006).  
 The registration method used by SPM is based on the work by Collignon et al. 
(Collignon et al. 1995), where the original interpolation method has been changed in 
order to give a smoother cost function. The images are also smoothed slightly, by 
means of their histograms. This is all in order to make the cost function as smooth as 
possible, to give faster convergence and less chance of local minima. A 3D rigid-
body model, parameterized by three translations and three rotations about the 
different axes, is used by means of voxel-to-voxel affine transformations. This 
approach is very efficient for brain anatomical district. 
 We chose Normalized Mutual Information (NMI) as the cost function to be 
optimized. The Mutual Information registration criterion states that the mutual 
information of the image intensity values of corresponding voxel pairs is maximal if 
the images are geometrically aligned. The results presented by Maes et al. (Maes et 
al. 1997) demonstrated that sub-voxel registration differences with respect to the 
stereotactic reference solution can be obtained for PET/MRI matching without using 
any prior knowledge about the gray-value content of both images and the 
correspondence between them. Mutual Information is the most intensively 
investigated criterion for registration of intra-individual human brain images. In 
addition, PET/MRI registration misalignment can be large with respect to the imaged 
field of view, then a criterion invariant to image overlap statistics is very important, 
such as the NMI proposed in (Studholme et al. 1999). 
 Since MET-PET and MRI multimodal images are written in a different space, an 
efficient resampling and interpolation method must be utilized. Although Nearest-
Neighbor and Trilinear interpolations are faster, B-Spline interpolation is 
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recommended when subject movement can occur in the different PET and MRI 
scans, because they are not acquired simultaneously. In particular, we used the 4th 
Degree B-Spline interpolation. 
 Two instances of PET/MRI co-registration are shown in figure 11, where the 
quality of the achieved registration can be qualitatively appreciated with the 
checkerboard images (figure 11a and figure 11d) as well as fused PET/MR images 
(figure 11b and figure 11e). In addition, joint histogram, that is a feature space 
constructed by counting the number of times a combination of grey values occurs 
contextually on source (MET-PET) and target (MRI) images was also computed and 
plotted (figure 11c and figure 11f). Along the axes of each joint histogram the grey 
values of the two images are represented: from left to right for source (MET-PET) 
and from bottom to top for target (MRI).  
 Original and final joint histograms prove the quality of the Normalized Mutual 
Information registration process, because pixel values are mainly redistributed on the 
histogram diagonal. 
 
 
Figure 11 Instances of PET/MRI co-registration using SPM via maximization of NMI: (a, d) 
checkerboard images of co-registered PET and MRI; (b, e) fused images; (c, f) corresponding original 
and final joint histograms for (b) and (e), respectively. 
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 5.2.4 Fully Automatic Co-Segmentation 
 
 It is worth noting, the smart combination of the two single modality pipelines in 
the flow diagram shown in 10. In particular, PET and MRI segmentation results are 
mutually exploited each other.  
 Firstly, the Interesting Updating Regions (IURs), obtained on PET images by the 
graph-based tumour segmentation method, are used for the generation of a properly 
area including the tumour on MR brain images. These ROI bounding regions are 
calculated adaptively on MR images using a Level Set method and then utilized by 
the MRI brain lesion segmentation method based on FCM clustering technique. 
 Lastly, MRI GTV masks are also combined with PET images, which are 
processed by the RW algorithm, in order to influence and refine tumour 
segmentation on PET images. 
 
 
 5.2.4.1 Interesting Uptake Region Detection 
 
 The fully automatic PET/MRI joint segmentation starts with the automatic 
identification of the PET slice with the highest SUV (SUVmax) on PET dataset 
previously co-registered with the corresponding MRI. The voxels with a SUV greater 
than 95% of SUVmax are marked as target seeds. The 8-neighborhood of the node 
with SUVmax, through searching in all 8 directions, is explored to identify the voxels 
with a SUV less than 30% of the average of target seed SUVs. In this way, 8 
background nodes are identified. Once the foreground and background seeds are 
automatically localized, the PET lesion is segmented using our enhanced RW 
method: the probability threshold to discriminate between target and background 
voxels is obtained slice by slice to follow the whole lesion volume. In this way, the 
method takes into account the intensity gradient and contrast changes of the 
metabolic lesion over the entire range of PET slices. Once the BTV has been 
extracted, the ROI of the first PET slice (the PET slice with the SUVmax) is 
propagated to the corresponding MRI dataset. In addition, the range of segmented 
PET slices with high uptake regions is also provided to the next processing phase, in 
order to generate efficiently a ROI bounding region for the tumour on MR images. 
 This information defines the so-called Interesting Uptake Region (IUR). 
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 5.2.4.2 ROI Bounding Region Generation 
 
 A coarse lesion delineation on MR images is required in order to define 
automatically a bounding region that encloses the actual GTV on MR slices. Hence 
user interaction, needed by the methods in (Militello et al. 2015) through a ROI 
selection tool, will be completely prevented and avoided. 
 Because of the variability of brain lesion in terms of location and intensity values, 
the definition of a valid ROI bounding region is not a trivial problem. A bad choice 
of the ROI bounding region on MR image can affect the whole FCM clustering 
process. Therefore, this task must be carried out not in a static way (e.g. using a 
simple morphological dilation or closing with a fixed structuring element), but rather 
adaptively by processing MRI input data. 
 This adaptive procedure starts on the lesion ROI found on SUVmax slice. This IUR 
is first dilated (using a structuring element represented by a disk of 3-pixel radius) 
and then utilized as a binary step function to initialize a Level Set method. A rough 
and over-estimated MRI brain lesion segmentation, based on the Distance 
Regularized Level Set Evolution (DRLSE) formulation proposed in (Li et al. 2010), 
is used to generate dynamically a bounding region that includes the brain lesion in 
the MR slice corresponding with the PET slice. Unlike Region Growing algorithm, 
DRLSE method allows a controlled and regular Level Set Function (LSF) evolution, 
by avoiding leaking in the brain tissue area. In short, level set methods represent an 
active contour as the zero level set of a higher dimensional function and determine 
the evolution of the contour. 
Let :  be a LSF defined on a domain  , the energy functional is defined by: 
)()()(:  ggp ALRE   (8) 
where: 
 0 , 0  and   are the coefficients of the energy functional terms pR , 
gL  and gA , respectively; 
   xdpRp  :)(     is the level set regularization term, where ),0[:p  is 
a potential function. In order to smooth the LSF effect and ensure accurate 
computation for curve evolution by maintaining the signed distance property 
1 , a potential function )(sp  with a minimum point at 1s  is chosen. In 
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particular, a double-well potential, with two minimum points at 0s  and 
1s , was used: 
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 xdgLg  )(:)(     is an energy functional that computes the line integral 
of the edge indicator function 2
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 (G is a Gaussian kernel with 
standard deviation   that is convoluted with the image I  to reduce the 
noise) along the zero level contour of   with the Dirac delta function  ; 
 xdgHAg  )(:)(     is an energy functional that calculates weighted area of 
the region  0)(:  xx  . This term is introduced to speed-up the motion of 
the zero level contour in the LSF evolution process, which is necessary when 
the initial contour is far away from the desired object boundary. Lastly, H  is 
the Heaviside step function, whose derivative is the Dirac delta function  . 
 In practice and for implementation purposes, the Dirac delta function   and 
Heaviside step function H  are approximated by their respective smooth version   
and H , defined as: 
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where   (usually set to 1.5) is a parameter that specifies the width of the Dirac Delta 
function and the slope of the Heaviside step function. 
 The overall energy functional in (8) can be minimized, given an initial LSF 
)()0,( 0 xx   , by solving the following gradient flow in the temporal variable 
),0[ t : 
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where )div(  is the divergence operator and the function pd , defined as sspd p )(' , 
has a diffusion effect on the LSF. In particular, in our approach, we used 
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 Therefore, the utilized LSFs take negative values inside the zero level contour and 
positive values outside. This choice causes the coefficient   to take negative value 
to expand the active contour. The DRLSE and the temporal partial derivative t  
were implemented as a finite difference numerical scheme. 
 Equation (8) is an edge-based geometric active contour model and represents an 
application of the general DRLSE formulation. This variational formulation 
demonstrates good adaptation segmentation results in different image processing 
contexts, thanks to the available free parameters. 
 In our implementation, on theoretical basis and experimental trials, we set the 
parameters as follows: 2.0 , 5 , 0.1 , 30 c , 8.0 , and a time step 
0.1t  It is worth to note that the parameter   needs to be carefully tuned. A non-
zero value forces the motion of the contour, but the resulting final contour may 
slightly deviate from the true object boundary due to the shrinking or expanding 
effect of the weighted area term. To avoid this, the final contour can be refined by 
further evolving the contour for a few iterations with 0  (e.g. ten iterations). Since 
it is required a first rough and over-estimated segmentation to define a ROI boundary 
region on MR images and we deal with weak object boundaries, a large value of   
may cause boundary leakage. For this reason, a relatively small   was chosen to 
reduce boundary leakage. 
 These computations are performed just once for each dataset. In fact, only one 
bounding region is determined via DRLSE-based segmentation and it is reported 
onto the other candidate MR slices. For this purpose, the range of PET slices with 
high uptake regions is also provided by the IUR detection steps, in order to construct 
a cylindroid (i.e. a cylinder with irregular-shaped bases) including the whole GTV 
brain lesion. Since PET and MRI tumour volumes may be distributed along different 
axial slices, the range of PET active slice is augmented by three slices on upper and 
lower sides, in order to ensure the total enclosing of the tumour into the cylindroid 
defined on the MRI dataset. 
 Three examples of ROI bounding regions delineated, on original MR images, by 
the DRLSE-based method are shown in 12. 
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Figure 12 ROI bounding region generation on MR images: three examples of bounding region 
determined via DRLSE-based method, starting from IUR imported from the corresponding SUVmax 
PET slice. 
 
 5.2.4.3 MRI Segmentation based on FCM clustering 
 
 As stated before in section 5.2.2, brain tumour segmentation on MR images is 
accomplished using the validated semi-automatic method described in (Militello et 
al. 2015). However, due to the automation of the segmentation process, the direct 
control of the human operator is lost during ROI bounding region manual 
delineation. Some MR images included in the cylindroids (defined by the steps in 
section 5.2.4.2), especially the most distant slices from the IUR, might include no 
brain tumours as well as anatomical parts with pixel values similar to enhancement 
regions (such as bone or epidermal tissue). 
 For the former case, MRI brain lesion segmentation method yields an empty ROI. 
For the latter case, a shape-based control on connected-components belonging to the 
cluster with the highest intensity pixels is also defined, by taking advantage of the 
pseudo-spherical appearance of metastatic tumours. When either skull bone or skin 
are included in the ROI bounding region, since IUR is located near brain boundary, 
other high-valued pixel areas may be erroneously segmented by the unsupervised 
FCM clustering algorithm. These areas are often characterized by a lengthened shape 
and may be removed by checking eccentricity (ratio between the foci distance related 
to an ellipse and its own major axis length) and extent (ratio between the pixels of 
the region and the bounding-box pixels) of the connected-components. Theoretically 
suitable and experimentally validated feature values for this refinement step are: 
 
(c) (a) (b) 
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 Figure 13 shows segmentation results on the images reported in figure 12. In 
particular, refinement steps can be appreciated in Figure 12c, where the region 
composed of the skin highest pixels included in the ROI bounding region is correctly 
removed by the shape-based controls. 
 
 
Figure 13 Examples of brain tumour segmentation on MR images (red contour), starting from the 
ROI bounding region (blue contour). A difficult case is shown in (c), where a lengthened hyper-
intense region of the head skin is detected by FCM clustering (yellow contour), but it is removed 
using the shape-based control. 
 
 5.2.4.4 Combining MRI Segmentation Results and PET Images 
 
 Lesion segmentation results on the morphologic brain MRI data are combined 
with the metabolic information of the co-registered PET images. This PET dataset 
represents the input of the RW algorithm. In this way, MRI GTV is utilized to 
combine the superior contrast of PET images with the higher spatial resolution of 
MR images. Each PET slice is weighted pixel-by-pixel according to the 
corresponding MRI binary masks. Nevertheless, an assumption that there is a one-to-
one correspondence between BTV and GTV is unrealistic. Lesions may have smaller 
uptake regions compared to GTV. In the same way, the PET lesion can show 
additional area compared to lesion boundaries in MR images. For this reason, we 
incorporate, with extreme caution, the MRI GTV binary mask in the RW 
segmentation procedure. In particular, PET pixels inside the corresponding MR 
target are multiplied by a 15% gain factor to slightly emphasize probable lesion area; 
PET pixels outside the corresponding MRI ROI masks are underestimated with a 5% 
factor in order to correct radioactivity spill-over and spill-out effects between tumour 
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and surrounding tissues taking advantage of the higher spatial resolution of MR 
images. 
 
 5.2.4.5 PET Segmentation based on Random Walker algorithm 
 
 The RW-based segmentation process on PET dataset is updated and repeated on 
PET dataset combined with MRI binary masks in order to achieve a new BTV, in 
this paper written also as BTVMRI. 
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Chapter 6 
 
 
Experimental Results  
 
 
6.1 Image Segmentation in PET 
 
The results reported in this section have been used to produce the following research 
papers: 
 
 A. Stefano, S. Vitabile, D. D’Urso, G. Russo, M. Ippolito, M. Sabini, O. 
Gambino, R. Pirrone, E. Ardizzone, and M. Gilardi, Head and Neck Cancer 
Tumor Volume Segmentation in PET images Using an Enhanced Random 
Walk Algorithm, Under Review at Medical & Biological Engineering & 
Computing. 
 A. Stefano, Vitabile S, Russo G, Ippolito M, Sardina D, Sabini MG, 
Gallivanone F, Castiglioni I, and Gilardi MC. A Graph-Based Method for 
PET Image Segmentation in Radiotherapy Planning: A Pilot Study, A. 
Petrosino (Ed.): ICIAP 2013, Part II, LNCS 8157, pp. 711–720, 2013. 
 A. Stefano, S. Vitabile, G. Russo, M. Ippolito, F. Marletta, C. D’Arrigo, D. 
D’Urso, M. Sabini, O. Gambino, R. Pirrone, E. Ardizzone, and M.C. Gilardi, 
An Automatic Method for Metabolic Evaluation of Gamma Knife Treatments, 
A. Petrosino (Ed.): ICIAP 2015, Part II, LNCS 9279, pp. 579–589, 2015. 
 A. Stefano, S. Vitabile, G. Russo, M. Ippolito, F. Marletta, C. D’Arrigo, D. 
D’Urso, M. Sabini, O. Gambino, R. Pirrone, E. Ardizzone, and M. Gilardi, A 
Fully Automatic Method for Biological Target Volume Segmentation of Brain 
Metastases, International Journal of Imaging Systems and Technology, In 
press. 
 
 
 6.1.1 Phantom Study Description 
 
 PET experimental measurements have been carried out by using radioactive 
National Electrical Manufacturers Association International Electrotechnical 
Commission (NEMA IEC) body phantom to estimate the accuracy of the proposed 
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PET segmentation method. The phantom consists of an elliptical cylinder (D1 = 24 
cm, D2 =30 cm, h= 21cm) with six spheres of different diameters (d1= 10 mm, d2 = 
13 mm, d3 = 17 mm, d4 = 22 mm, d5 = 26 mm, d6 = 37 mm) positioned at 5.5 cm 
from the centre of the phantom. Spheres, and background are filled with radiotracer 
with different ratios between measured sphere radioactivity concentration and 
measured background radioactivity concentration (S/B). The proposed segmentation 
method is evaluated by matching the sphere delineation with the ground truth in the 
CT images. The image acquisition is performed on Discovery 690 with time of flight 
and Discovery STE PET/CT scanners by General Electric Medical Systems. A single 
PET slice consists of a matrix of 256x256 voxels of 2.73x2.73x3.27 mm3 voxel size, 
while a single CT slice consists of a matrix of 512x512 voxels of 1.36x1.36x3.75 
mm
3
 voxel size. 
 
 
 6.1.2 Patient Study Description 
 
 
 6.1.2.1 HNC  
 
 Eighteen patients with HNC, that have been referred for a diagnostic PET/CT 
scan before radiotherapy treatments, are enrolled. Patients fast for 12 h before the 
PET examination and are intravenous injected with FDG. The PET/CT oncological 
protocol begins 60 min after the injection. Patients breathe normally during the PET 
and CT examinations, and scanning is executed from the top of the skull to the 
middle of the thigh with the arms along the body. The BTV is manually defined by 
two expert radiation oncologists in consensus with the nuclear medicine physician 
drawing a 2D outline slice by slice: the active tumour volume includes the tumour 
area with an intense tracer uptake respect to background activity level. 
 
 
 6.1.2.2 Brain Cancer 
 
 Twelve brain acquisitions without head fixation are performed using the same 
PET/CT scanner used in phantom studies. Patients have fast for 4 hours before PET 
exam and are intravenous injected with MET. The PET protocol begins 10 minutes 
after the injection. The BTV is manually defined by an expert radiation oncologist in 
consensus with the nuclear medicine physician drawing a 2D outline slice by slice: 
the active tumour volume includes the tumour area with an intense tracer uptake 
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respect to background MET activity level. The clinical feasibility evaluation of the 
proposed method is done by comparing the automatic with the manual BTV 
segmentation. 
 
 
 6.1.3 Evaluation Metrics 
 
 The validation of the proposed method is achieved on phantom experiments. The 
same algorithm is then applied in patients that have been referred for a diagnostic 
PET/CT scan before treatment to assess the clinical feasibility of our segmentation 
method. In phantom studies the CT region must match with the PET region: the 
proposed segmentation method is evaluated by matching the sphere delineation with 
the ground truth in the CT images.  
 The segmentation performance is evaluated by the Dice Similarity Coefficient 
(DSC), median Hausdorff Distance (HD), and True Positive Volume Fractions 
(TPVF) (Udupa et al. 2006). The specificity (100 – false positive volume fractions) 
is not considered because the target voxel number with respect to the background 
voxel number is very small (a single PET slice consists of 65536 voxels while the 
largest spheres -or lesions- in a single slice is < 400 voxels). 
 DSC is a measurement of spatial overlap between segmented and manual BTV: a 
DSC of one describes a perfect match between the two volumetric segmentations, 
while a DSC of zero describes no overlap between the BTVs.  
 
DSC is defined as: 
%100
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 (13) 
 HD is a shape dissimilarity metric measuring the most mismatched boundary 
pixels between automatic and manual BTV: a small average of HD value means an 
accurate segmentation, while a large average of HD value means no accuracy.  
 TPVF indicates the fraction of the total amount of tissue inside the target lesion 
(sensitivity). 
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6.1.4 Results 
 
 
 6.1.4.1 K-RW and AK-RW Method Validation 
 
 Phantom images are used for validation of the methods proposed in section 
3.3.1.1 (K-RW method) and 3.3.1.2 (AK-RW method).  
 Figure 14 shows the DSC averaged on different spheres in each NEMA IEC body 
phantom experiment. The size of the spheres is known, and the accuracy of 
delineation methods is evaluated. Phantoms have been studied with an S/B of 2-3 for 
the NEMA (a), 3-5 for the NEMA (b), 5-6 for the NEMA (c), and 6-7 for the NEMA 
(d). The 30% and 90% thresholds of the SUVmax used to find the background and 
target seeds in section 3.3.1.1 are the best among those evaluated (threshold ranges 
from 10% to 40% and from 70% to 99%, respectively for background and target 
seeds).  
 The DSC range of PET delineation using the K-RW algorithm is found to be from 
83.51% (phantom “d”) up to 99.86% (phantom “a”) for the sphere < 17 mm diameter 
with a mean of 92.95±5.90% and from 87.71% (phantom “a”) up to 99.43% 
(phantom “d”) for the sphere > 17 mm diameter with a mean of 96.17±3.48%. 
Considering all spheres, phantom “b” has the best mean (97.33±1.87%) and phantom 
“a” the worst one (93.29±5.44%).  
 As regards the AK-RW algorithm, the DSC range is found to be from 80.92% 
(phantom “c”) up to 99.98% (phantom “b”) for the sphere < 17 mm diameter with a 
mean of 89.55±7.16% and from 93.42% (phantom “a”) up to 99.39% (phantom “b”) 
for the sphere > 17 mm diameter with a mean of 97.32±1.73%. Considering all 
spheres, phantom “b” has the best mean (97.23±3.56%) and phantom “a” the worst 
one (93.45±4.77%).  
 The HD range of PET delineation using the K-RW algorithm is found to be from 
1.27 mm (phantom “c”) up to 2.71 mm (phantom “b”) for the sphere with a diameter 
< 17 mm (HD mean = 1.72±0.28 mm) and from 0.1 mm (phantom “a”) up to 2.73 
mm (phantom “b”) for the sphere with a diameter > 17 mm (HD mean = 0.8±0.13 
mm).  
 The AK-RW algorithm HD range is found to be from 1.35 mm (phantom “c”) up 
to 2.81 mm (phantom “b”) for the sphere with a diameter < 17 mm (HD mean = 
1.81±0.19 mm) and from 0.1 mm (phantom “a”) up to 2.73 mm (phantom “b”) for 
the sphere with a diameter > 17 mm (HD mean = 0.9±0.11 mm). 
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 The average TPVF using the K-RW algorithm is found to be 93.18±5.73% for 
phantom “a”, 98.70±3.20% for phantom “b”, 95.85±4.28% for phantom “c”, 
96.81±3.71% for phantom “d”.  
 The average TPVF using AK-RW algorithm is found to be 93.08±9.66% for 
phantom “a”, 98.37±2.13% for phantom “b”, 97.30±1.11% for phantom “c”, 
98.74±2.32% for phantom “d”. The average specificity (100 – FPVF) is ~ 100% in 
all experiments. 
 
 
Figure 14 Mean DSC obtained from NEMA IEC body phantoms. Phantoms have a measured S/B of 
2-3 for phantom “a”, 3-5 for phantom “b”, 5-6 for phantom “c”, and 6-7 for phantom “d”. 
 
 An analysis of the time performance showed that both algorithms are fast: the 
segmentation time for larger spheres (the whole volume consists of 12 slices) is 
around 4 seconds. Obviously, the time necessary for the choice of the probability 
threshold by the user in K-RW delineation time is excluded. 
 
 
 6.1.4.2 HNC 
 
 Manual delineation is obtained by averaging the segmentations performed by two 
nuclear medicine physicians with an inter-observer agreement of 86.51±3.65%.  
 Figure 15 reports the quantitative comparison between semi-automatic and 
manual segmentation. Results based on the DSC, HD, and TPVF show that the K-
RW and AK-RW algorithms outperform the best among other tested algorithms 
(original RW, Threshold 40%, and Region Growing). In addition, region growing 
and RW methods often failed to properly delineate bifurcated lesions: figure 16 
shows the segmentation task of two lesions with a complex shape obtained using the 
different methods. In particular, the figure shows the PET slice where the target 
lesion splits into two regions. In both examples, AK-RW (cyan) and K-RW 
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(magenta) methods correctly delineate the bifurcated lesions while region growing 
and RW methods fail in delineating the bifurcation. The threshold (yellow) method 
correctly delineates the first bifurcated lesion but it requires an accurate VOI 
(volume of interest) definition by the user to enclose the lesion volume and to restrict 
the delineation bounds. 
 
 
Figure 15 Mean DSC obtained from NEMA IEC body phantoms. Phantoms have a measured S/B of 
2-3 for phantom “a”, 3-5 for phantom “b”, 5-6 for phantom “c”, and 6-7 for phantom “d”. 
 
 
Figure 16 Segmentation examples of two bifurcated lesions (A and B rows) are shown. First column: 
AK-RW method (cyan) and ground truth (blue) are overlaid. Second column: K-RW method 
(magenta) and ground truth (blue). Third column: the RW method (black) and ground truth (blue). 
Fourth column: the region growing method (red) and ground truth (blue). Fifth column: the threshold 
method (yellow) and ground truth (blue). 
 
 In this way, false positives are removed, but the segmentation time increases 
considering the need to delineate the VOI. Instead, the proposed methods are able to 
follow the bifurcation identifying the centroids of hot regions slice after slice; also 
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qualitative assessment indicates that AK-RW and K-RW methods are better than 
other approaches to properly follow the whole PET lesion volume. 
 
 
 6.1.4.3 AA-RW Method Validation 
   
 Phantoms are studied with an S/B 6-7 for the NEMA (a), 5-6 for the NEMA (b), 
and 3-5 for the NEMA (c).  
 For the small sphere (diameter < 17 mm), the DSC range of the AA-RW 
delineation is found to be from 81.23% up to 99.99%, with a mean of 89.44±6.19%. 
For the large spheres (diameter ≥ 17 mm), the AA-RW DSC range is found to be 
from 95.01% up to 99.89%, with a mean of 98.30±1.66%. The average TPVF is 
98.74±2.32% for phantom “a”, 97.30±1.11% for phantom “b”, and 98.37±2.13% for 
phantom “c”. HD ranges from 2.03 mm up to 3.66 mm for the small spheres, with a 
mean of 2.57±0.46 mm. In the same time, HD ranges from 1.69 mm up to 2.73 mm 
for the large spheres, with a mean of 1.96±0.28 mm. 
 The resultant DSC, TPVF, and HD scores of all implemented methods (original 
RW, Threshold 40%, Region Growing, and Fuzzy C-Means) are shown in figure 17. 
Mean values and standard deviations of the DSC, TPVF, and HD for small and large 
spheres and for the seven methods are given in table 1.  
 Time performance analysis shows that the algorithm is fast: the segmentation time 
for the larger sphere (the whole volume consists of 12 slices) is about 3 seconds. 
 
Figure 17 Mean DSC, TPVF, HD and the standard deviation obtained for phantom studies. 
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 Small spheres (d<17mm)  Large spheres (d≥17mm) 
Method DSC(%) TPVF(%) HD(mm)  DSC(%) TPVF(%) HD(mm) 
AA-RW 89.44±6.19% 99.57±1.06 2.57±0.46  98.30±1.66% 97.92±1.03 1.96±0.28 
RW(0.5) 82.74±8.17% 96.17±1.76 5.24±0.68  91.04±2.19% 93.92±1.15 3.06±0.66 
RW(0.7) 84.77±7.69% 98.57±1.11 4.89±0.91  93.46±2.16% 94.92±1.13 2.95±0.35 
RW(0.9) 85.94±6.83% 99.03±1.21 4.01±0.29  94.24±1.23% 96.18±1.24 2.38±0.36 
RW(1) 85.71±7.35% 98.95±1.15 3.86±0.48  95.36±1.19% 96.83±1.13 2.19±0.46 
T40% 81.23±8.90% 95.07±1.25 6.71±0.59  90.44±2.02% 89.92±2.25 4.26±0.58 
RG 83.40±8.04% 97.81±1.04 4.99±0.88  91.25±1.19% 94.22±1.82 3.35±0.48 
FCM 81.93±6.90% 95.97±1.29 6.14±0.73  89.91±3.12% 88.22±2.89 4.43±0.60 
 
Table 1 Mean values of the DSC, TPVF, and HD values for small and large spheres. 
 
 6.1.4.1 Brain Cancer 
 
 The AA-RW delineation is not subjected to both intra and inter-operator 
variability. All segmented radioactive lesions are homogenous (one single peek is 
visually detected on the histogram of lesion voxel values). The metabolic volume is 
3.02±2.24 ml (range: 1.19-10.44 ml). 
 The DSC range of PET delineation using the AA-RW algorithm ranges from 
81.7% up to 92.6%, with a mean of 88.57±3.22%. The HD ranges from 1 mm up to 
3.67 mm, with a mean of 1.96±0.62 mm. The average TPVF is found to be 
91.13±6.75% (range: 76.3% - 100%). High DSC and TPVF values, and a low HD 
value confirm the accuracy of the proposed method.  
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 The difference between manual and automatic contour delineation in three MET-
PET examinations is shown in figure 18.  
 
 
 
Figure 18 Three different segmentation examples of MET uptake regions. AA-RW method (non-
continuous line) and manual segmentation (continuous line) are overlaid. 
 
 
 6.1.5 Discussion 
 
 PET delineation is a critical task due to physical factors (size of the detector 
crystals, positron range in matter, non-collinearity of annihilation gamma-rays and 
detector scatter) which leads to a blurred margin of the lesions. To date, manual 
contouring is the most commonly used method in radiotherapy planning. The manual 
segmentation approach is dependent on the experience of the nuclear physician 
limiting the measurement accuracy. In addition, the manual segmentation is time-
consuming and impaired by inter and intra-observer variability. Clinical analysis of 
PET studies is performed on software platforms with predefined window-level 
setting. This setting can be liberally modified by the nuclear physician, altering the 
visual appearance of PET lesions. To reduce these issues, several automatic methods 
have been presented, but few clinical studies are available and there is no consensus 
for proper BTV determination. Efforts to generate an automatic or semi-automatic 
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framework for a precise PET contouring are needed in order to increase the BTV 
reproducibility and reliability in the planning of radiotherapy treatment. 
 The aim of this thesis is to validate a PET image segmentation method based on 
RW. An adaptive probability value is introduced to make the proposed method 
independent from the choice of the β factor in the Gaussian weighting function (5). 
 In addition, the proposed algorithm identifies the RW foreground and background 
seeds to obtain an automatic method, satisfying a very critical requirement in a 
clinical environment. The fully automatic identification of target and background 
seeds is feasible in brain studies because the MET PET datasets for Gamma-Knife 
treatments include only the brain area avoiding the possible presence of false 
positives in other anatomic regions. Differently, in total body PET examinations, 
such as those carried out in HNC study, a user interaction to manually identify the 
target lesion is always needed (normal structures such as brain, heart, bladder, and 
kidneys normally have high FDG uptake). 
 In addition, the proposed methods are very fast if compared with the time needed 
for manual segmentation in a clinical environment. 
 High DSC and TPVF, and low HD values confirm the accuracy of the RW-based 
methods. In HNC study, the AK-RW algorithm is slightly less accurate than the K-
RW method, but it is expected because K-RW is a semi-supervised algorithm: the 
user can choose the best among probability threshold values to properly delineate the 
PET spheres. AK-RW obtains good segmentation results besides having the benefit 
of requiring a low user interaction effort and low levels of user’s specialist 
knowledge being independent of the choice of the probability threshold value to 
discriminate target from background regions.  The development of user independent 
techniques able to perform good segmentation is crucial in a clinical environment. In 
addition, AK-RW method follows the whole lesion volume taking into account the 
gradient of intensity and contrast changes of the PET lesion in different slices.  
 A slight drop in the accuracy in phantom experiments occurs for lesions with 
diameter < 1.7 cm. In patient’s studies, the mean metabolic volume is greater than 3 
ml (lesions with a sphere-equivalent diameter > 1.8 cm): since target dimensions are 
larger than 2–3 times the FWHM (full width at half maximum) of the point spread 
function of the PET scanner, the underestimation of metabolic activity caused by 
PVE can be assumed to be negligible. In the lesions with a sphere-equivalent 
diameter < 1.7 cm a partial volume correction method could be included in the 
algorithm. 
 Despite the fact that many studies use the information of co-registered PET and 
CT images to identify features for distinguishing a lesion from the background and, 
consequently, for PET image segmentation, we believe that BTV extraction is 
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independent from anatomical segmentation being inappropriate to consider a 
matching between anatomical and metabolic regions, with special reference in HNC 
district. Head and neck lesions may have different uptake margins compared to 
anatomical margins; PET and CT show complementary features. In a phantom study 
the CT region must match the PET region. This is not true in HNC patient studies. It 
is not appropriate to consider a one-to-one relationship between anatomical and 
functional images. The metabolic volume cannot match the tumor anatomic 
extension, showing different and additional information including not visible 
metastases using traditional radiologic techniques. In addition, mis-registration 
between the two series can occur due to patient’s motion. Then, the assumption of 
identical HNC boundary in PET and CT images is questionable and unrealistic. 
Uptake regions may be larger\smaller than the anatomical boundary of the tumor due 
to cellular activation in target tissues. I believe that a correct delineation of BTV 
must be obtained without incorporating anatomical information or incorporating 
them with great attention. For example, although the patients with brain cancer 
undergo a PET/CT examination, CT has strong limitations for target delineation of 
brain metastases and this makes impossible to apply a multi-modal PET/CT image 
segmentation. Differently, the high resolution of the MRI is important for the 
illustration of the anatomy, and a co-registration PET/MRI is essential in the high-
precision radiotherapy of brain tumors: a study to determine simultaneously tumor 
contours on PET and RM images is the topic of the fifth chapter. 
 
 
6.2 Metabolic Evaluation of Oncological Treatments 
 
The results reported in this section have been used to produce the following research 
papers: 
 
 Stefano, Russo G, Ippolito M, Cosentino S, Murè G, Baldari S, Sabini MG, 
Sardina D, Valastro L, Bordonaro R, Messa C, Gilardi MC and Soto Parra H. 
Evaluation of erlotinib treatment response in non-small lung cancer using 
metabolic and anatomic criteria, QJ Nucl Med Mol Imag, EPUB ahead of 
print. 
 Stefano, N. Porcino, G. Banna, G. Russo, V. Mocciaro, G. Anile, S. Gieri, S. 
Cosentino, G. Murè, S. Baldari, M.G. Sabini, D. Sardina, F. Fraggetta, S. 
Vitabile,  M.C. Gilardi, and M. Ippolito. Metabolic Response Assessment in 
Non-Small Cell Lung Cancer Patients after Platinum-Based Therapy: A 
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Preliminary Analysis, Current Medical Imaging Reviews, vol. 11, n. 4, pp. 
218-227, 2015. 
 Stefano, S. Vitabile, G. Russo, M. Ippolito, F. Marletta, C. D’Arrigo, D. 
D’Urso, M. Sabini, O. Gambino, R. Pirrone, E. Ardizzone, and M.C. Gilardi, 
An Automatic Method for Metabolic Evaluation of Gamma Knife Treatments, 
A. Petrosino (Ed.): ICIAP 2015, Part II, LNCS 9279, pp. 579–589, 2015. 
 
 
 6.2.1 Clinical Case Description 
 
 
 6.2.1.1 Erlotinib treatment 
 
 Twenty patients, with NSCLC stage IV after at least one course of chemotherapy, 
with a performance status of asymptomatic, or symptomatic but completely 
ambulatory, scheduled to undergo Erlotinib therapy are considered (11 men and 9 
women, mean age: 64.2±11.8 years, range 38 to 79 years). Twelve patients (60%) 
have a history of smoking. The histopathologic diagnosis is: 4 adenocarcinomas 
(20%), 12 non-adenocarcinomas (60%), 4 NOS (not otherwise specified) (20%).  
 All patients receive the same Erlotinib neoadjuvant chemotherapy treatment (150 
mg orally once daily for 45 days) at the Department of Oncology, Garibaldi Nesima 
Hospital of Catania.  Patients undergo a FDG PET/CT scan before treatment (PETI) 
and after administration of 3 doses of Erlotinib at 48 h (PETII) for early monitoring.  
A further metabolic follow-up is planned at the end of Erlotinib treatment, 45 days 
from the start of therapy (PETIII).   
 Six patients drop out at the last PET scan (PETIII): 2 patients undergo PET/CT 
scan in a different PET institution, 2 patients interrupt therapy, and 2 patients need of 
additional therapy. For the 14 patients who completed the protocol, morphological 
diagnostic CT scans after the administration of 100 ml of intravenous iodate contrast 
material (Iomeprolo, Iomeron 300) are performed before and 45 days after the 
initialization of Erlotinib treatment.  
 For each PET scan, the lesion presenting with the highest FDG uptake is 
considered (not necessarily the same lesion on three PET studies) according to 
EORTC, PERCIST and RECIST classifications to assess metabolic and anatomic 
response. The ratio (SUVratio) between SUVmax and mean SUV in the liver is 
considered, in order to limit intra-subject uptake variability. The region of interest in 
the liver is placed on the central region of the right lobe. EORTC and EORTC ratio 
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criteria are applied to classify SUVmax and SUVratio, respectively. 
 In addition, the metabolic volume is calculated using the method described in the 
third chapter. Median values of metabolic (EORTC, and PERCIST) and 
morphological (RECIST) response classifications are statistically compared using 
Wilcoxon signed-rank test. Disease-Free Survival (DFS) and Overall Survival (OS) 
time of response classifications are calculated by the Kaplan-Meier test. Median OS 
and median DFS are compared between responders and non-responders using a long-
rank test. A p value less than 0.05 is considered statistically significant. 
 
6.2.1.2 Platinum-based therapy 
 Seventeen inoperable patients with stage IV NSCLC are enrolled. PET studies is 
carried out before the initiation of platinum-based therapy and after the first cycle of 
chemotherapy for an early therapy monitoring. Patients received a platinum-based 
chemotherapy according to the American Society for Clinical Oncology or European 
Society for Medical Oncology guidelines, with carboplatin or cisplatin in 
combination with another third generation agent, with possible addition of 
bevacizumab. PET/CT measurements without contrast are performed on a time-of-
flight Discovery 690 scanner (General Electric Medical Systems). Patients fast for 12 
h before the PET examination and are intravenous injected with FDG. The PET/CT 
oncological protocol begins 60 min after the injection. Patients breathe normally 
during the PET and CT examinations, and scanning is executed from the top of the 
skull to the middle of the thigh with the arms along the body. Patients underwent a 
18F-FDG PET/CT examination without contrast before platinum based 
chemotherapy (PET0) and 28±6 days after the initiation of therapy (PETI) for early 
monitoring.  Morphological diagnostic CT scans before and between day 49 and 88 
(median, 68 days) after the initiation of treatment are performed. 
 The lesions with the highest uptake in each patient are evaluated according to 
EORTC considering a cut-off of 15% (EORTC15%) and 25% (EORTC25%) to 
discriminate between patients who respond from those who do not respond to 
treatment. Moreover, PERCIST and RECIST classifications are evaluated too. 
 Receiver operating characteristic curves are used to obtain cut-off points for 
therapy evaluation based on variations of TLG and MTV in sequential scans. Overall 
Survival (OS) time is calculated by the Kaplan-Meier test. A p value less than 0.05 is 
considered statistically significant. 
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    6.2.1.3 Gamma Knife Treatment 
 
 Eighteen patients with brain metastases that have been referred for a diagnostic 
PET/CT scan before Gamma Knife treatment are enrolled. PET brain acquisitions 
without head fixation are performed. Patients have fast for 4 hours before PET exam 
and are intravenous injected with MET. The PET protocol begins 10 minutes after 
the injection.  
 Lesion segmentation is used to evaluate therapeutic response using SUVmax, 
MTV, and TLG variations in sequential scans. MTV provides metabolic volumetric 
information of the tumors; TLG, defined as MTV x (average SUV within the MTV), 
combines the volumetric and SUV information, to try to obtain a better evaluation of 
the treatment response. 
 Variations (Δ) in PET parameters are normalized to baseline: 
 Δ(%) = 100 x (post-treatment – baseline)/baseline. 
 
 
 6.2.2 Results 
 
 
 6.2.2.1 Erlotinib treatment response  
 
 Metabolic Response Evaluation at 48 h 
 As regards the EORTC and EORTC ratio classifications, some patients are 
classified differently, but the classes of metabolic response are overall equal: 7 
patients show a Partial Metabolic Response (PMR), 10 patients a Stable Metabolic 
Disease (SMD), and 3 patients a Progressive Metabolic Disease (PMD).  
 According to PERCIST: 2 PMR, 17 SMD, and 1 PMD.  
 There is a significant difference in response evaluation between EORTC and 
PERCIST (Wilcoxon signed-rank test, p<0.02). To perform the Kaplan-Meier 
analyses, the patients are split into responders (PMR) and non-responders (SMD and 
PMD). Figure 19 shows Kaplan-Meier curves for EORTC, EORTC ratio, and 
PERCIST classifications. The analyses show that only EORTC proved a significant 
prognostic factor for predicting DFS (hazard ratio [HR] =0.364; 95% confidence 
interval [CI], 0.149-0.889; p=0.011) and OS (HR = 0.332; 95% CI, 0.133-0.827; 
p=0.009) with a median of 103 and 410 days, respectively, in responder patients. 
Non-responders have a median DFS of 47 days and a median OS of 104 days. 
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EORTC ratio and PERCIST are not a significant factor associated with DFS (p-
value=0.054 and p-value=0.89, respectively) and OS (p-value=0.19 and p-
value=0.68, respectively) in this study.  
 Table II summarizes median DFS and OS days for responder and non-responder 
patients. 
 
 Metabolic and Morphological Response Evaluation at 45 days 
 The morphological responses according to RECIST are as follows: 4 Partial 
Response (PR) and 10 Progressive Disease (PD). Metabolic responses according to 
EORTC and EORTC ratio criteria are coincident (all patients are equally classified): 
5 PMR, 5 SMD, 4 PMD. According to PERCIST: 4 PMR, 6 SMD, and 4 PMD. 
There is a significant difference in the results of response classification between 
metabolic criteria (EORTC, EORTC ratio, and PERCIST) and RECIST (p<0.04).  
 RECIST is a significant prognostic factor for DFS (HR =4.070; 95% CI, 1.383-
11.972; p=0.002) and OS (HR =2.620; 95% CI, 0.8806-7.795; p<0.046). Both 
EORTC and PERCIST show significant prognostic factors for DFS (EORTC: HR = 
0.319; 95% CI, 0.061-1.667; p=0.028; PERCIST: HR =0.245; 95% CI, 0.0835-
0.722; p=0.001), but only the PERCIST criteria show a good agreement with OS 
(EORTC: p=0.65; PERCIST: HR =0.3817; 95% CI, 0.1283-1.1356; p=0.046). 
 For responder patients, median DFS is 287.5 days for the RECIST and PERCIST 
and 79.5 days for EORTC. For non-responder patients, median DFS is comparable 
for all response criteria (50 days for RECIST and PERCIST, and 49 for EORTC). 
RECIST and PERCIST show a good prognostic factor for the median OS: 480 vs 
174 days (for responders versus non-responders). 
 Table III summarizes median DFS and OS days for responders and non-
responders. Figure 20 shows Kaplan-Meier curves for RECIST, EORTC, and 
PERCIST classifications.  
 Two representative PET lesions for a patient affected by multiple metastases are 
presented in figure 21 (PETI, PETII, PETIII). The lesion with the highest 18F-FDG 
uptake is the same in PETI and PETII but different in PETIII. Metabolic response at 
48 h is PMD according to EORTC (∆SUV=+53.3%), and SMD according to 
PERCIST (∆SULpeak =+21.4%). Metabolic response at 45 days is PMD for EORTC 
and PERCIST (∆SUV=+25.87% and ∆SULpeak =+41.2%), whereas morphological 
response according to RECIST is PD. The patient presents recurrence of disease at 
51 days and died at 147 days.   
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Figure 19 Kaplan-Meier analyses at 48 h. DFS (column A) and OS (column B) in patients after 
administration of 3 doses of Erlotinib according to EORTC, EORTC ratio and PERCIST based on the 
classification between responders (PMR) and non-responders (SMD and PMD). Only EORTC is a 
significant prognostic factor for predicting DFS and OS (p<0.011). 
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Figure 20 Kaplan-Meier analyses at 45 days. DFS and OS in patients according to RECIST, EORTC, 
and PERCIST based on the classification between responders and non-responders. RECIST and 
PERCIST are significant prognostic factors for predicting DFS and OS (p<0.05). EORTC is a 
significant prognostic factor for predicting DFS (p=0.028) but not OS (p=0.65). 
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Table II Comparison of Metabolic Response at 48 h. 
 
Table III Comparison of Metabolic and Morphological Response at 45 days. 
 
 
 
Figure 21 Two representative PET lesions for a patient affected by multiple metastases. 
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 6.2.2.2 Platinum-based therapy response 
 
 For the 17 patients who completed the protocol, 11 are men and 6 women (mean 
age: 65±11 years, range 35 to 81 years). Fifteen (88.23%) had a history of smoking 
and among these 8 patients (52.94%) are current smokers. The histopathologic 
diagnosis is: 11 adenocarcinomas (64.71%), 4 squamous carcinomas (23.53%), and 2 
not otherwise specified (11.76%).  
 According to EORTC25% 5 patients show a PMR, 9 patients a SMD, and 3 patients 
a PMD; according to EORTC15% 9 PMR, 5 SMD, and 3 PMD; according to 
PERCIST 4 PMR, 10 SMD, 3 PMD; according to RECIST 1 CR, 4 PR, 4 SD, and 8 
PD. MTV and TLG averages of responder patients are lower than those of non-
responder patients for all classifications. EORTC15% and RECIST classifications 
show SUV and SUL averages lower in patients who responded to treatment rather 
than in non-responders.  
 The Kaplan-Meier analyses show that a statistically significant difference between 
responder and non-responder patients is recognized according to EORTC15% 
(HR=2.97 ; CI, 0.89-9.95; p =0.0251) and RECIST (HR=4.80 ; CI, 1.61- 14.27; 
p=0.0154) classifications. No statistically significant difference between responders 
and non-responders is observed in the EORTC25% and PERCIST classifications 
(p=0.13 and p=0.18, respectively).  
 Figure 22 shows Kaplan-Meier curves for all classifications.  
 
 
Figure 22 OS curves according to EORTC25%, EORTC15%, PERCIST and RECIST based on the 
division between responders (continuous line) and not responders (non-continuous line). 
 
 For responders, median OS is 423 days for the EORTC15%, and 595 for RECIST. 
For non-responders, median OS was 194.5 and 238 for EORTC15% and RECIST, 
respectively. 
 The ROC study suggests a ∆TLG cut-off value of -36%, and a ∆MTV cut-off 
value of -8%. ∆TLG (HR=3.22; CI, 1.07-9.71; p =0.0145) and ∆MTV (HR=4.77; CI, 
1.21-18.71; p =0.0005) are significant factors for OS.  
 In addition, in the same way in which EORTC proposes an early threshold of 15% 
after one cycle of chemotherapy, the ROC analysis to identify an early PERCIST 
threshold of 17% (PERCIST17%) rather than the conventional cut-off of 30% is 
used. In this way, PERCIST17% is a significant factor for OS (HR= 4.63; CI, 1.45-
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14.75; p =0.0016), unlike the original PERCIST that is inadequate to discriminate 
between patients who respond from those who do not respond to treatment. Figure 23 
shows Kaplan-Meier curves. ∆TLG and PERCIST17% discriminations between 
responder and non-responder patients show a median OS of 492 days for responder 
patients and 238 (∆TLG) and 194.5 (PERCIST17%) days for non-responder patients. 
∆MTV reveals a median of 423 versus 188 days. 
 
 
Figure 23 OS curves according to PERCIST17%, ∆TLG, ∆MTV using cut-off points obtained by ROC 
analysis to discriminate between patients who respond (continuous line) from those who do not 
respond to treatment (non-continuous line). 
 
  
 
 
Figure 24 The highest 18F-FDG uptake lesion before treatment (I) and after treatment (II) with 
relative MTV in two patients with multiple metastases. Patient A is classified as a responder in all 
metabolic classifications showing 60% decrease in SUV and SUL, 80% decrease in TLG, and 42% 
decrease in MTV. Patient B is classified as a responder in EORTC25% and EORTC15% (-26%), and as a 
non-responder according to PERCIST (-18%), ∆TLG (+33%), and ∆MTV (+58%).  
 
 The 1-year OS are 100% and <25% for responder and non-responder patients, 
respectively, in agreement with RECIST, ∆TLG and PERCIST17%. Both EORTC15% 
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and ∆MTV have poorer OS than RECIST and ∆TLG (78% versus 12% and 78% 
versus 0%, respectively). 
 Representative PET images for two patients (A and B) affected by multiple 
metastases are presented in figure 24. The lesion with the highest FDG uptake is the 
same in PET0 and PETI in both patients. For the first patient, metabolic response is 
PMR according to EORTC (both EORTC25% and EORTC15%), PERCIST, ∆TLG, 
and ∆MTV. The patient is classified as CR according to RECIST and is censored for 
OS after 498 days. 
 
 
 6.2.2.3 Gamma Knife Treatment 
 
 About Gamma Knife treatment response evaluation, results are shown in Table 
IV. Most patients show the same treatment response trend using SUVmax, MTV, and 
MTV variations in sequential scans. Differently, the third patient shows a minimal 
change in SUVmax (-1.00%) and great variation in the metabolic tumor mass and in 
TLG (-61.12% and -59.43%, respectively). Patients number 4, and 9 show a positive 
ΔSUVmax (+9.47% and +14.73%, respectively), and a negative ΔTLG, and ΔMTV (-
16.89% and -8.50%, +49.98% and +39.74%, respectively).  
 The sixth patient study shows a positive ΔMTV (+24.85%), and a negative ΔSU-
Vmax (-44.36%), and ΔTLG (-26.15%). At last, patients number 8 and 12 show a 
visual disappearance of metabolic lesions indicating a complete metabolic response 
(CMR) to treatment. 
 
 
Table IV Metabolic response obtained on the segmented lesions for each patient. 
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 6.2.3 Discussion 
 
 The early identification of responder and non-responder patients is mandatory to 
avoid inefficient treatments and to preserve the patient’s quality of life. Unnecessary 
administration of expensive, potentially non-curative, and toxic drugs in subtypes of 
cancers that are refractory or resistant to specific treatment could be avoided by the 
choice of an appropriate strategy for the evaluation of therapy response. 
 For early response, after 48 h from the first Erlotinib administration, PET images 
were assessed according to EORTC, EORTC ratio, and PERCIST classifications. 
Kaplan-Meier analyses showed that EORTC was able to discriminate responder from 
non-responder patients, predicting DFS and OS (p-value<0.011), and that EORTC 
ratio and PERCIST were inadequate to predict DFS and OS (p-value>0.05). The 
difference between the PERCIST threshold (30%) and the EORTC threshold (15%) 
in differentiating responders from non-responders could explain this result in the 
early evaluation.  
 For treatment response, at 45 days from the first Erlotinib administration, both 
morphological (RECIST) and metabolic (EORTC, EORTC ratio and PERCIST) 
classifications were evaluated. Statistical analyses showed that RECIST and 
PERCIST were able to classify responders from non-responders (p-value<0.05). 
EORTC and EORTC ratio classifications were not suitable to discriminate 
responders from non-responders: this result could be affected by statistical variation 
of SUVmax due to the high noise in PET images. 
 In Platinum-based therapy response study, the Kaplan-Meier analysis showed that 
RECIST, EORTC15%, ΔTLG, and ΔMTV proved to be a significant prognostic factor 
for predicting OS. Conversely, EORTC15% and PERCIST classifications were 
inadequate to discriminate between patients who respond from those who do not 
respond to treatment.  EORTC15% classification identified 9 patients with a PMR, 
PERCIST classification identified only 4 patients with a PMR: if we evaluate the 
data with the PERCIST analysis, 5 patients, classified as non-responders, should 
change therapy, which, instead, according to EORTC15% recommendations are 
classified as responders and could continue with the therapy that is working. The 
presence of an early threshold in EORTC15% could explain this result.  The 1-year 
OS was 100% for responder patients, in agreement with RECIST and ΔTLG 
analyses. EORTC15% had a poorer OS (78%) than RECIST and ΔTLG. In addition, 
in the second case study in figure 21, ΔTLG classified the patient as a non-responder 
unlike the RECIST and EORTC classifications that classified the patient as a 
responder (the patient died after 132 days): TLG has the advantage that it reflects 
both the metabolic information and the lesion size, whereas RECIST is exclusively 
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based on anatomical information and EORTC is mainly based on metabolic 
information. 
 Al last, MTV and TLG can reflect metabolic changes in sequential PET scans 
after Gamma Knife treatment throughout the entire tumor mass. These parameters 
should be more accurate methods of detecting global changes than a single-pixel 
value measurement such as SUVmax. The results showed that the patient number 3, 4, 
and 9 could be a demonstration of this theory. The sixth patient showed a positive 
ΔMTV, and a negative ΔTLG that is indicative of partial response to treatment. TLG 
combines the volumetric (MTV) and the semi-quantitative parameter (SUV) 
information: it probably provides a better evaluation of the prognosis compared to 
MTV. In conclusion, PET delineation in neurosurgical radiosurgery appears helpful 
for assessing the effects of therapy in brain metastases. The developed method could 
be used as a Medical Decision Support System to help clinicians in treatment 
response evaluation of oncological patients.  
 
 
6.3 Multimodal Image Segmentation 
  
The results reported in this section have been used to produce the following research 
paper: 
 
 L. Rundo, A. Stefano, C. Militello, G. Russo, M. G. Sabini, C. D’Arrigo, F. 
Marletta, M. Ippolito, G. Mauri, S. Vitabile, and M. C. Gilardi. A Fully 
Automatic Approach for Multimodal PET and MR Image Segmentation in 
Gamma Knife Treatment Planning, submitted to Computer Methods and 
Programs in Biomedicine, Elsevier. 
 
 A total of 19 brain metastatic tumors originating from several primary cancers, 
undergone stereotactic neuro-radiosurgery, were retrospectively considered in the 
present study. All the patients (mean age ± standard deviation: 60 ± 9.80 years; 
median age: 57 years; age range: 48÷78 years) were treated with Leksell Gamma 
Knife® model C at Cannizzaro Hospital in Catania, Italy. 
 Both MRI and PET datasets were acquired for these subjects. PET and MR 
imaging data were obtained by two different scanners in two different times. MRI 
dataset, used for Gamma Knife treatment planning, was scanned a few days after 
MET-PET study.  Representative instances of input brain MR and PET image pairs 
are shown in figure 25. 
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 PET brain acquisitions without head fixation are performed using the on time of 
flight PET/CT Discovery 690 by General Electric Medical Systems (Milwaukee, WI, 
USA). Patients fast for 4 hours before PET exam and are intravenous injected with 
MET. The PET protocol begins 10 minutes after the injection. PET images consist 
into a matrix of 256x256 voxels of 1.1719x1.1719x3.27 mm3 voxel size.  
 All available MRI datasets are acquired on the Gyroscan Intera 1.5T MR Scanner 
(Philips Medical System Eindhoven, the Netherlands), before treatment, for the 
planning phase. MR images are “T1w FFE” (T1-weighted Fast Field Echo) contrast-
enhanced sequences. MRI acquisition parameters are: TR: 25 ms, TE: 1.808-3.688 
ms, matrix size: 256 × 256 pixels, slice thickness: 1.5 mm, slice sacing: 1.5 mm, 
pixel spacing 1.0 mm. Therefore, each size voxel is 1.0×1.0×1.50 mm3. Thanks to 
the Gadolinium-based contrast agent, brain lesions appear as enhanced hyper-intense 
zones. Sometimes a dark area might be present due to either edema or necrotic tissue.  
 
 
 
Figure 25 Examples of original input brain images concerning Gamma Knife patients: (a, c) MR 
slices and (b, d) the nearly respective corresponding PET slices. 
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 6.3.1 Evaluation Metrics 
 
 Volume-based, overlap-based and spatial distance-based metrics are considered, 
in order to measure similarity and correlation concerning PET and MRI 
segmentation approaches. Assuming PET and MRI segmentations as two different 
processes, the evaluation metrics were computed according to the formulations 
presented in (Fenster & Chiu 2005). These formulations are suitably generalized to 
quantify the similarity and correlation between two different segmentation 
procedures on images defined on the same space (e.g. same image or fused images). 
 The aim is to demonstrate that PET and MR imaging convey different 
information. For this purpose, similarity and correlation measures were considered.  
 Let BTV and GTV be the results achieved by the PET and MRI 3D segmentation 
approaches, respectively.  
 The quantitative measure that best points out the similarity between PET and MRI 
volumes is the volumetric similarity (VS), namely the absolute difference between 
volumes divided by the volumes sum: 
 
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GTVBTV
GTVBTV
VS 


 1
abs
1  (14) 
where VD  is the volumetric distance. 
 However, this volume-based metric does not take into account the intersection 
between PET and MRI segmentation at all. Therefore, overlap-based metrics must be 
considered. In particular, the DSC (see see section 6.1.3). Since medical images are 
usually characterized by noise and the HD is generally sensitive to outliers, a more 
stable distance formulation must be considered. The average distance (AVD), that is 
the HD averaged over all points in A and B, is defined by:  
)},(),,(max{ ABdBAdAVD   (16) 
where 
 
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bamin)1(),(  is the directed average distance. 
 Another similarity measure is the Jaccard index ( JI ), which is the ratio between 
the cardinality of the intersection and the cardinality of the union calculated on the 
two segmentation results: 
DSC
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 DSC is always larger than JI except at extrema %}100 ,0{ , where they take equal 
values. In both measures, higher values imply greater similarity between PET and 
MRI segmentations. 
 Lastly, in order to take into account the correlation of all samples belonging to 
two different points clouds, a variant of the Mahalanobis distance (MHD) is used: 
)()( 1 GTVBTV
T
GTVBTVMHD  
  (14) 
where 
BTV  and GTV  are the means of the two 3D segmentations. Furthermore,   is 
the common covariance of the two sets and is given by 
||||
||||
GTVBTV
GTVBTV GTVBTV


 . 
 In the proposed joint segmentation approach, two different PET segmentation 
results are computed:  
 BTV, by considering PET images alone (section 5.2.1), and  
 BTVMRI, by considering by considering PET/MRI co-segmentation (section 
5.2.4.5).  
Therefore, BTV and BTVMRI can be used interchangeably in equations, 
depending on the usage context.  
 
 
 6.3.2 Results 
 
 Firstly, volumes measured on PET and MRI data are reported and, for a 
quantitative assessment, PET/MRI volume difference and centroid distance were 
calculated for each lesion. 
 Figure 26 shows segmentation results obtained by the proposed multimodal 
PET/MRI segmentation method on the input image pairs reported in figure 25. In 
addition, the corresponding GTV and BTVMRI volume rendering is reported. 
  Other three interesting examples obtained by the proposed multimodal 
segmentation method can be visually and qualitatively evaluated in Figure 27. It is 
worth to observe that the margin of enhancement of tumors in MRI datasets are not 
always correlated with high uptake regions in PET images. Segmentation results of 
PET images combined with GTV MRI masks are very stable (magenta boundaries in 
Figure 27), even if GTV is quite different. In figure 27c, PVE on PET image is 
reduced by using MRI binary masks. 
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Figure 26 Results achieved by the proposed multimodal PET/MRI segmentation method on the input 
image pairs reported in Figure 25. The BTVMRI (magenta contour) and GTV (green contour) are 
superimposed: (a) boundaries computed on PET and MR images are nearly overlaid; (b) the two ROIs 
are very different in this case. At the bottom right, a blow-up of the lesion regions is shown in both 
cases. 3D volume reconstruction of brain tumors in (a) and (b) are shown the lesions in (c) and (d), 
respectively.  
 
Figure 27 Graphical examples of co-segmentation results achieved by the proposed multimodal 
PET/MRI approach, where GTV (green contour), BTV (blue contour) and BTVMRI (magenta contour) 
ROIs are overlaid on the corresponding fused PET/MRI slice. Three metastatic tumors in different 
anatomical regions of human brain are considered: (a) temporo-parietal, (b) limbic, and (c) occipital 
regions. The images are displayed with 2× zoom factor. 
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Volumes, calculated for each brain tumor imaged on MRI and PET modalities, are 
shown in Table V. Absolute average volume difference between BTV, BTVMRI and 
GTV, were also calculated, in order to evaluate either overestimation or 
underestimation of PET functional imaging with respect anatomical MRI data, 
before and after GTV binary mask combination into PET images. In addition, 
Euclidean distance between PET and MRI volume centroids (centers of mass) was 
reported. Mean BTV and GTV values and their average absolute volume difference 
attest that tumor regions are imaged and represented differently on PET and MRI 
datasets. Furthermore, high standard deviation in BTV and GTV measurements 
proves that we are dealing with metastatic lesions characterized by various types and 
dimensions. On the other hand, BTVMRI measurements follow a different trend 
because BTVMRI segmentation is influenced by the combination of GTV masks and 
PET images. 
Table V Brain tumor volume measurement for each metastatic tumor using MR and PET imaging. 
Total average and standard deviation calculated on 19 brain lesions are also reported. 
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 Although we slightly integrate MRI ROI masks with PET datasets during BTVMRI 
computation, this conservative choice frequently reduces radioactivity spill-over and 
spill-out effects, by exploiting higher MRI spatial resolution. This is evident in the 
examples shown in Figure 27. Moreover, BTVMRI measurement standard deviation is 
lower than BTV and GTV ones. This means that multimodal PET/MRI segmentation 
yields more stable results with respect to single modality segmentations, since both 
metabolic and morphological imaging are considered. These experimental evidences 
are corroborated by the achieved absolute volume difference values, where BTVMRI 
has about the same difference with GTV and BTV. Volume centroid distances reflect 
the aforementioned situation, too. To show the statistical distribution of GTV, BTV, 
and BTVMRI measurements, boxplots are reported in figure 28. 
 Boxplots confirm that BTVMRI has a more uniform distribution than BTV on 
tumor volume variability range, by taking into account GTV contribution. Moreover, 
BTV has a positive skewed distribution characterized by outliers above the upper 
whisker. Accordingly, BTVMRI samples are characterized by approximately the same 
median of BTV values, but BTVMRI statistical distribution tends to GTV distribution 
shape. The above observations, based on numerical experimental results, are 
qualitatively supported by the graphical multimodal PET/MRI segmentation results 
in figure 29. 
 
 
Figure 28 Boxplots of tumor volume measurements: GTV, BTV and BTVMRI. Whisker value is 1.5 in 
all cases. 
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 To measure the degree of dependence between GTV, BTV, and BTVMRI, both 
Pearson’s correlation coefficient and Spearman’s rank correlation coefficient were 
calculated for each comparison (Table VI). Spearman’s correlation yields different 
information with respect to Pearson’s correlation, since Spearman’s is less sensitive 
to strong outliers that are in the tails of both samples. In fact, outlier importance is 
limited to the value of its rank.  
 
 
Figure 29 Two examples of segmentation results obtained by the single modality PET method (BTV) 
versus those obtained by the multimodal PET/MRI approach after the PET data updating based on the 
results of the MRI brain lesion segmentation (BTVMRI). (a, c) GTV (green contour), BTV (blue 
contour), and BTVMRI (magenta contour) ROIs overlaid on the corresponding fused PET/MRI slice; 
(b, d) 3D representation of BTV and BTVMRI volume brain tumors. 
 
 As expected, GTV revealed greater correlation to BTVMRI, especially according to 
Spearman. In addition, BTV and BTVMRI are significantly correlated, using both 
Pearson and Spearman correlation coefficients. Accordingly, scatter diagrams in 
figure 30 represent graphically these numerical results. 
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 The comparisons of GTV, BTV, and BTVMRI for the available brain lesions 
(statistical samples) are also visualized using Bland-Altman plots in Figure 31. 
Bland-Altman plots showed the greatest differences between GTV and BTV, 
confirming the trend observed previously. 
 Table VII shows tumor volume-based and overlap-based metrics for PET and 
MRI segmentation methods. Both volume-based and overlap-based metrics 
demonstrated that GTV was, on average, more similar to BTVMRI than BTV. The 
highest mean values and the lowest standard deviation of the evaluation measures 
were obtained in BTVMRI  and BTV comparisons. To provide a graphical 
representation of the statistical distribution of results, corresponding boxplots of 
volume-based and overlap-based evaluation metrics are also reported in Figure 32. 
 Table VIII reports the values of spatial distance-based metrics achieved by the 
proposed multimodal PET/MRI segmentation approach in the experimental trials. 
Distance-based metrics values agreed with achieved volume-based and overlap-
based measurements, showing the same trend. To visualize dispersion and variability 
of achieved results, corresponding boxplots of spatial distance-based evaluation 
metrics are also reported in Figure 33. 
 
 
Table VI Correlation measure between GTV, BTV, and BTVMRI, using Pearson’s correlation 
coefficient and Spearman’s rank correlation coefficient. 
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Figure 30 Scatter diagrams of tumor volume measurements: (a) BTV versus GTV; (b) BTVMRI versus 
GTV; (c) BTV versus BTVMRI. Red dashed line is the line of equality. In the upper part of each sub-
figure, Pearson and Spearman correlation coefficients with the corresponding significance level are 
also reported. 
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Figure 31 Bland-Altman plots of tumor volume measurements: (a) BTV versus GTV; (b) BTVMRI 
versus GTV; (c) BTV versus BTVMRI. 
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Table VII Achieved tumor volume-based and overlap-based metrics for GTV, BTV, and BTVMRI 
segmentations. Total average and standard deviation calculated on 19 brain lesions are also reported. 
 
 
Figure 32 Boxplots of tumor volume-based and overlap-based metrics calculated for GTV, BTV and 
BTVMRI segmentations: (a) Volumetric similarity; (b) Dice similarity coefficient; (c) Jaccard index.  
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Table VIII Achieved tumor spatial distance-based metrics for GTV, BTV, and BTVMRI 
segmentations. Total average and standard deviation calculated on 19 brain lesions are also reported. 
 
 
Figure 33 Boxplots of tumor spatial distance-based metrics calculated for GTV, BTV and BTVMRI 
segmentations: (a) Hausdorff Distance; (b) Average distance; (c) Mahalanobis distance.  
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 6.3.3 Discussion 
 
 The proposed fully automated multimodal segmentation method introduces 
several novelties and advantages. Firstly, two computer-assisted single modality 
segmentation approaches for PET and MR images are used. These single modality 
segmentation methods are certainly more effective and reliable on PET and MRI 
datasets, with respect to approaches that unify information into a single graph. In 
these cases, no significant anatomical and functional changes have to be assumed 
between the scans to directly construct the hyper-graph (Bagci et al. 2013). 
 Secondly, IURs detected on PET images are not blindly propagated to MRI 
segmentation algorithm, but properly modified according to MRI data using the 
developed ROI bounding region generation method. This ad hoc MRI-driven 
method, based on LSFs, finds adaptively a valid bounding region in order to 
eliminate user intervention, required by the MRI brain tumor segmentation method in 
(Militello et al. 2015). Hence, two existing and efficient single modality processing 
pipelines are combined in a smart fashion. In particular, PET and MRI segmentation 
results are mutually exploited each other. 
 Lastly, this fully automated approach is very robust and reliable, also due to the 
brain anatomical district imaging. We focused on the application domain regarding 
brain tumors that underwent Leksell Gamma Knife stereotactic radiosurgery. In fact, 
the fully automatic identification of target IURs is feasible because MET-PET 
datasets for stereotactic neuro-radiosurgery treatment planning include only the brain 
area avoiding the possible presence of false positives in other anatomic regions. 
Differently, in total body FDG-PET examinations user interaction to manually 
identify the target lesion is always needed (normal structures such as brain, heart, 
bladder, kidneys, and ureters normally have high FDG uptake). Accordingly, these 
co-segmentation software implementations platform must provide manual seeding 
facilities in addition to automated multimodal segmentation algorithm. 
 Although an one-to-one relationship between two different structural images of 
the same abnormal region could be reasonable, the assumption of identical lesion 
contours in both functional and morphologic images is often infeasible in many 
anatomical regions (Bagci et al. 2013). For instance, depending on the metabolic 
characteristics of the cells within a lung tumor, it may not take up a radiotracer in all 
its volume, or uptake region may be larger than the anatomical boundary of the 
tumor due to cellular activation in nearby tissues. Further issues are introduced by 
combining more than two structural modalities, such as MRI and CT, with metabolic 
PET imaging. 
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 In this study, PET and MRI datasets regarding the same subject were acquired at 
two different times (MRI is scanned a few days after MET-PET) by two different 
dedicated PET/CT and MRI scanners, respectively. This represents a non trivial 
problem in co-segmentation domain, because an efficient and accurate multimodal 
co-registration is required. Instead, state of the art about co-segmentation methods 
process mostly simultaneous PET/CT or PET/MRI acquisitions. Of course, the 
potential of hybrid imaging (PET/CT and PET/MRI systems) overcomes image 
registration issues by giving multimodal images contextually. 
 Achieved experimental results showed that GTV and BTV segmentations are 
statistically correlated but have not higher degree of similarity. In fact, GTV and 
BTV measurements as well as evaluation metrics values (volume-based, overlap-
based, and spatial distance-based metrics) corroborate that MRI and MET-PET 
convey different but complementary imaging information. The output of the 
proposed multimodal PET/MRI segmentation method combines PET and MR 
imaging and is similar to both BTV and GTV. Moreover, BTVMRI segmentation 
reduces radioactive spill-over and spill-out effects between tumor and surrounding 
tissues, taking advantage of the higher spatial resolution of MRI. 
 Finally, PET imaging should be usually consider by clinicians in order to 
determine a CTV that takes into account the “active” part of the cancer in addition to 
anatomical tumor boundaries. According to these findings, it is appropriate to 
include PET images in stereotactic neuro-radiosurgery treatment planning. 
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Chapter 7 
 
 
Discussions and Conclusions  
 
 PET segmentation in radiotherapy is a critical task due to the lack of consistency 
in tumor contour, low image resolution, and relatively high level of noise and 
heterogeneity of FDG uptake within a lesion. Nevertheless, accurate lesion 
segmentation in PET imaging is essential for an accurate quantification of prognosis 
assessment and therapy response. Qualitative visual interpretation is the most 
commonly used method. The manual segmentation method is dependent on the 
experience of the nuclear physician limiting the measurement accuracy. In addition, 
it is time-consuming and impaired by inter- and intra-observer variability that is due 
to subjectivity and sensitivity to the display window level settings. To reduce these 
issues, several automatic methods have been presented but few clinical studies are 
available and there is no consensus for proper BTV determination.  
 To date, CT and MR imaging are considered to be the standard for target volume 
delineation in radiotherapy. On the other hand, CT and MR imaging does not show 
the biological features of tumors. For this reason, PET has been introduced in the 
radiotherapy field to assist radiation oncologists in clinical routine. Despite the fact 
that many studies use the information of co-registered PET and CT images to 
identify features for distinguishing a lesion from the background and, consequently, 
for PET image segmentation, I believe that BTV extraction is independent from 
anatomical segmentation being inappropriate to consider a matching between 
anatomical and metabolic regions, with special reference in HNC district. I believe 
that a correct delineation of BTV must be obtained without incorporating anatomical 
information or incorporating them with great attention. For example, MRI is crucial 
for the illustration of the anatomy of brain tumors: for this reason, a study to 
determine simultaneously tumor contours on PET and RM images is a topic of this 
thesis. 
 In addition, to identify oncological lesions in whole-body PET scans, a 
completely automatic detection method cannot be implemented since healthy organs 
such as brain, heart, bladder, and kidneys normally have a high FDG uptake, and, 
consequently, user interaction is mandatory. Vice versa, this is feasible in brain 
MET-PET studies. 
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 In this thesis, the semi-automatic segmentation algorithm based on the RW 
formulation of Grady (L. Grady 2006)  has been enhanced.  
 In HNC studies, the key strategies include k-means clustering to obtain refined 
target seed locations within pre-segmented lesions and a strategy to adaptively 
determine the appropriate threshold to be applied on the probabilistic output of RW 
in order to obtain the final tumor segmentation. The RW algorithm with a k-means 
algorithm embedded to identify centroids of hot regions is proposed to obtain an 
appropriate segmentation in complex lesions. In addition, the user can manually 
change the probability, rather the fixed one of 50% of the original RW method, to 
discriminate target from background voxels in order to select the value that optimizes 
the segmentation. We call this method “K-RW”. Second, an extension of the 
previous method to adaptively determine the probability threshold to discriminate 
lesion from background voxels is implemented. For this reason, we call this method 
“Adaptive K-RW (AK-RW)”. These methods segment PET images from SUV and 
they are very fast in a clinical environment if compared with the time needed for 
manual segmentation. Naturally, the AK-RW method is slightly less accurate than 
the supervised K-RW method, but it is expected because the selection of probability 
threshold is done automatically. AK-RW obtains good segmentation results besides 
having the benefit of requiring a low user interaction effort and low levels of user’s 
specialist knowledge being independent of the choice of the probability threshold 
value to discriminate target from background regions. The development of user 
independent techniques able to perform good segmentation is crucial in a clinical 
environment.  
 The accuracy of the proposed methods is optimal in phantom studies: high DSC 
and TPVF values and low HD and FPVF values confirm the robustness and the 
accuracy of the two methods. A DSC rate greater than 90% is almost always 
observed in the larger spheres. The clinical results underline that the proposed 
methods are superior to other methods minimizing the difference between manual 
and automatic lesion segmentations and, especially, also delineating complex 
volumes unlike other state-of-the-art methods. The methods commonly used in the 
literature have shown an acceptable delineation under specific conditions especially 
when the uptake concentration is homogeneous. In many patient studies, the lesions 
have complex shapes, such as bifurcated lesions, and nonhomogeneous uptake. In 
these cases, these methods fail in lesion delineation. The proposed methods take into 
account these issues providing a better segmentation according to the accuracy 
required in radiotherapy field to prevent potential disease progression.  
 A drop in the accuracy can occur for small lesions; this is compatible with the 
large errors in the volume estimation reported for small tumor volume. The PVE for 
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smaller objects is one of the most important factors impacting the quality and the 
quantitative accuracy in PET imaging (Soret et al. 2007). The images are blurred due 
to the limited spatial resolution of PET scanners and small lesions appear larger. For 
this reason, a PVE correction method has been developed (Stefano et al. 2014; 
Gallivanone et al. 2011). 
 The aim of the brain cancer study is to make the proposed segmentation method 
fully automatic and user independent identifying automatically the foreground and 
background seeds. The fully automatic identification of RW seeds is feasible because 
the MET PET datasets for Gamma-Knife treatments include only the brain area 
avoiding the possible presence of false positives in other anatomic regions. In 
addition, the adaptive probability threshold for each patient ranges from 25.28% up 
to 70.50% with a mean of 41.49±10.68% indicating how this factor is different both 
from patient to patient and from the fixed value of 50% of the original RW method. 
 This result highlights the importance of adopting the proposed enhanced version 
of the existing algorithm of Grady (Grady, 2006) to adaptively determine the 
appropriate threshold to be applied on the probabilistic output of RW method. 
 The developed methods have been used to assess the metabolic response in three 
different clinical studies. The early stratification of responder and non-responder 
patients is mandatory to avoid non-curative treatments preserving the patient’s 
quality of life. PET imaging is a useful technique to discriminate between patients 
who respond from those who do not respond to treatment: in particular, TLG has the 
advantage that it reflects both the metabolic information (SUV) and the lesion size 
(BTV). 
  At last, a fully automated multimodal segmentation method for Gamma Knife 
treatment is proposed. In this way, the BTV can be used to modify the GTV in order 
to treat the brain lesions more precisely combining the complementary information 
of tissues from both anatomical and functional domains: MRI GTV is utilized to 
combine the superior contrast of PET images with the higher spatial resolution of 
MR images. The proposed multimodal method exploits two PET and MRI 
segmentation methods, which have been properly combined together and improved. 
In particular, BTV and GTV segmentation results are mutually exploited each other 
in order to influence and refine CTV delineation.  
 In conclusion, the proposed methods are very powerful in terms of PET image 
and PET/MRI image segmentation, and may be used daily as a Medical Decision 
Support Systems to enhance the current methodology performed by healthcare 
operators in radiotherapy treatments. 
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